Identification of new genetic syndromes with epilepsy by whole-exome sequencing by Muona, Mikko
Identification of New Genetic Syndromes with 
Epilepsy by Whole-Exome Sequencing
INSTITUTE FOR MOLECULAR MEDICINE FINLAND AND
NEUROSCIENCE CENTER AND
RESEARCH PROGRAMS UNIT, MOLECULAR NEUROLOGY
FACULTY OF MEDICINE AND
DOCTORAL PROGRAMME IN BIOMEDICINE
UNIVERSITY OF HELSINKI
 
FOLKHÄLSAN INSTITUTE OF GENETICS
MIKKO MUONA
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis 44/2016
44/2016





































Recent Publications in this Series
24/2016 Niina Markkula
Prevalence, Predictors and Prognosis of Depressive Disorders in the General Population
25/2016 Katri Kallio
The Roles of Template RNA and Replication Proteins in the Formation of Semliki Forest Virus 
Replication Spherules
26/2015 Hanna Paatela
Role of Dehydroepiandrosterone in High-Density Lipoprotein-Mediated Vasodilation and in 
Adipose Tissue Steroid Biosynthesis
27/2016 Johanna Mäkelä
Neuroprotective Effects of PGC-1α Activators in Dopaminergic Neurons
28/2016 Sandra Söderholm
Phosphoproteomic Characterization of Viral Infection
29/2016 Mariann Lassenius
Bacterial Endotoxins in Type 1 Diabetes
30/2016 Mette Ilander
T and NK Cell Mediated Immunity in Chronic Myeloid Leukaemia
31/2016 Ninja Karikoski
The Prevalence and Histopathology of Endocrinopathic Laminitis in Horses
32/2016 Michael Backlund
Regulation of Angiotensin II Type 1 Receptor by Its Messenger RNA-Binding Proteins
33/2016 Stanislav Rozov
Circadian and Histaminergic Regulation of the Sleep-Wakefulness Cycle
34/2016 Bárbara Herranz Blanco
Multi-Approach Design and Fabrication of Hybrid Composites for Drug Delivery and Cancer 
Therapy
35/2016 Siri Tähtinen
Combining Oncolytic Immunotherapies to Break Tumor Resistance
36/2016 Katri Sääksjärvi
Diet, Lifestyle Factors, Metabolic Health and Risk of Parkinson’s Disease  – A Prospective 
Cohort Study
37/2016 Alexandre Borrel
Development of Computational Methods to Predict Protein Pocket Druggability and Profile 
Ligands using Structural Data
38/2016 Gonçalo Barreto
Innate Immunity in Osteoarthritis: The Role of Toll-Like Receptors and Cartilage Derived 
Mediators in the Disease Progression
39/2016 Alexey Yukin
Animal Models of Early Brain Disorders: Behavioural and Electrophysiological Approaches
40/2016 Satu Valo
Western Diet and Genetic Predisposition as Risk Factors of Colon Cancer
41/2016 Riccardo Siligato
Hormonal Regulation of Primary and Secondary Growth in the Root of 
Arabidopsis thaliana
42/2016 Janne Tynell
Virus-Host Interactions of Emerging Respiratory Pathogens
43/2016 Katri Korpela









IDENTIFICATION OF NEW GENETIC 






Mikko Muona, MSc 
 
 
Institute for Molecular Medicine Finland (FIMM), 
Research Programs Unit, Molecular Neurology, Faculty of Medicine,  
Neuroscience Center, 
Doctoral Programme in Biomedicine, 
University of Helsinki, Finland 
and 










To be presented, with the permission of the Faculty of Medicine, University of 
Helsinki, for public examination in Biomedicum Helsinki, Lecture hall 2, 




















Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam  
Universitatis Helsinkiensis (44/2016) 
 
ISSN 2342-3161 (paperback) 
ISBN 978-951-51-2255-1 (paperback) 
Hansaprint Oy 
Helsinki 2016 
ISSN 2342-317X (PDF) 
ISBN 978-951-51-2256-8 (PDF) 
http://ethesis.helsinki.fi  
Supervised by Professor Aarno Palotie, MD, PhD 
  Institute for Molecular Medicine Finland (FIMM) 
  University of Helsinki, Helsinki, Finland and 
The Broad Institute of MIT and Harvard 
Boston, MA, USA 
   
  Professor Anna-Elina Lehesjoki, MD, PhD 
Folkhälsan Institute of Genetics, Helsinki, Finland 
and Research Programs Unit, Molecular Neurology 
and Neuroscience Center 
University of Helsinki, Helsinki, Finland 
 
Thesis advisory  Docent Päivi Saavalainen, PhD 
committee Department of Bacteriology and Immunology, 
Haartman Institute and 
Research Programs Unit, Immunobiology, 
University of Helsinki, Helsinki, Finland 
 
  Professor Hannes Lohi, PhD 
Department of Veterinary Biosciences and Research 
Programs Unit, Molecular Neurology 
University of Helsinki, Helsinki, Finland and 
  Folkhälsan Institute of Genetics, Helsinki, Finland 
 
Reviewed by Docent Marjo Kestilä, PhD 
  Department of Government Services  
National Institute for Health and Welfare  
Helsinki, Finland 
 
  Helen V. Firth DM, FRCP, DCH 
East Anglian Medical Genetics Service, 
Addenbrooke's Hospital, Cambridge University 
Hospitals 
Cambridge, UK and 
Wellcome Trust Sanger Institute 
Hinxton, Cambridge, UK 
 
Opponent  Professor Joris Veltman 
Department of Human Genetics, Donders Centre for 
Neuroscience, Radboud University Medical Center, 
Nijmegen, the Netherlands and Department of 
Clinical Genetics, Maastricht University Medical 























































































Epilepsies are a heterogeneous group of central nervous system diseases 
characterised by recurrent epileptic seizures. They are one of the most 
common neurological diseases with a lifetime prevalence of ~4%. Epileptic 
seizures are also a common comorbidity of various neurobiological disorders 
where epilepsy is not the primary diagnosis. Most epilepsies have a genetic 
origin, either monogenic or polygenic, however, the causal genetic variants 
have remained unknown in a substantial proportion of individuals with 
epilepsies.  
Over the past decade, technological advances in DNA sequencing have 
allowed the characterisation of the genetic basis of human disorders rapidly 
and efficiently. One of the most widely used methods is whole-exome 
sequencing (WES) where genetic variants in the protein coding regions of the 
genome, the exome, are captured. Even though the exome constitutes only 
~1.5% of the genome, the majority of disease-causing variants underlying 
severe, monogenic diseases are located in the protein coding regions.  
Here, we aimed to decipher the molecular genetic basis of severe epilepsy 
syndromes by utilising WES to identify disease-causing genetic variants in 
patients without a genetic diagnosis. We studied patients with progressive 
myoclonus epilepsy (PME, n=84) or severe infantile-onset epileptic 
syndromes (n=30), which are one of the most devastating forms of genetic 
syndromes with epilepsy and characterised by frequent, pharmacoresistant 
seizures and poor prognosis. Given that the patients had undergone genetic 
testing to varying extent prior to this study, we specifically aimed to establish 
novel genes and molecular biological mechanisms underlying these 
syndromes.  
We made substantial progress in understanding the genetic architecture 
and molecular basis of the studied syndromes. For PMEs, we established a 
new major genetic cause and also expanded the genotypic and phenotypic 
spectrum of previously established disease genes. For severe infantile-onset 
epileptic syndromes, we identified one new, definite causal gene and one that 
requires identification of additional patients to confirm the causal role. The 
three newly identified disease genes represent three different molecular 
functions that together give new insight on epileptogenic mechanisms.  
The new PME subtype is caused by a heterozygous missense variant 
c.959G>A (p.Arg320His) in KCNC1 that was identified in 11 unrelated 
patients (13%) in the PME exome sequencing cohort. We have subsequently 
identified six additional patients. The gene encodes a potassium ion channel 
KV3.1 that has an important role in generating action potentials in the central 
nervous system, with the mutation disrupting the ability to transport 
potassium ions across the cell membrane. This mutation occurs in most 
families de novo, that is, it is a newly arising mutation. Based on the 
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estimated mutation rate, the recurrent KCNC1 mutation is a worldwide cause 
of PME with likely hundreds of affected individuals globally. 
In five families with altogether nine affected siblings, we identified 
compound heterozygous variants in UBA5 as the cause of an infantile-onset 
syndrome characterised initially by irritability, followed by epilepsy, dystonic 
movements, moderate to severe intellectual disability, microcephaly and 
stagnation of development. The gene encodes an activating enzyme for 
UFM1, which is a small ubiquitin-like protein that is conjugated to its target 
proteins. The function of the highly conserved UFM1 conjugation system is 
still largely unknown. Functional analysis of the UBA5 mutants suggest that 
the identified variants cause reduced enzymatic activity of UBA5. Symptoms 
of the UBA5 patients and our findings in the central nervous system specific 
knockout mice for Ufm1 together indicate that UFM1-cascade is essential for 
normal development and function of the central nervous system. 
Finally, we identified compound heterozygous variants in ADAM22 as the 
likely cause of the disease in a patient with an infantile-onset rapidly 
progressing encephalopathy with epilepsy and cortical atrophy. The gene 
encodes a postsynaptic protein that functions as a receptor for LGI1, and we 
show that the identified variants abolish the ability of ADAM22 to bind to 
LGI1. The LGI1-ADAM22 complex is an antiepileptogenic factor regulating 
synaptic transmission throughout life. Highlighting the important role of this 
complex, knockout of Adam22 and Lgi1 in mice causes lethal epilepsy. 
Autosomal dominant LGI1 variants also cause epilepsy in humans. 
Identification of a patient with loss-of-function variants in ADAM22 suggest 
that also this gene is linked to epilepsy in humans. This connection should be 
confirmed through identification of additional affected individuals with 
ADAM22 variants. 
Altogether, this thesis demonstrates the power of WES in identification of 
causal genetic variants even in phenotypically heterogeneous patient cohorts 
subjected to prior genetic screenings. The findings improve diagnostics of 
these syndromes, increase knowledge of the underlying molecular 
mechanisms and potentially aid in developing new therapeutic interventions. 
Finally, for these families, establishment of the genetic diagnosis ends years 
of uncertainty and frustration of not knowing the cause of the disease and 




Epilepsiat ovat heterogeeninen joukko keskushermostosairauksia, jotka 
ilmenevät toistuvina epileptisinä kohtauksina. Niiden elämänaikainen 
esiintyvyys on noin 4 % eli ne ovat yksiä yleisimmistä neurologisista 
sairauksista. Epileptisiä kohtauksia esiintyy myös osana muita 
keskushermoston sairauksia, joissa epilepsia ei ole päädiagnoosi. Useimmat 
epilepsiat ovat geneettisiä – joko mono- tai polygeenisiä – mutta tautia 
aiheuttavat geneettiset variantit jäävät tunnistamatta merkittävällä osalla 
epilepsiaa sairastavista. 
Viimeisen vuosikymmenen aikana teknologinen kehitys DNA-
sekvensoinnissa on mahdollistanut ihmisen sairauksien geneettisen taustan 
selvittämisen nopeasti ja tehokkaasti. Yksi käytetyimmistä menetelmistä on 
eksomisekvensointi, jossa geneettiset variantit koko perimän proteiinia 
koodaavilla alueilla – eli eksomissa – pystytään tunnistamaan. Vaikka 
eksomi on vain noin 1,5 % koko perimästä, suurin osa vakavia monogeenisiä 
sairauksia aiheuttavista muutoksista sijaitsee proteiinia koodaavilla alueilla. 
Tässä väitöstutkimuksessa tavoitteenamme oli selvittää vakavien 
epileptisten oireyhtymien molekyyligeneettistä taustaa hyödyntämällä 
eksomisekvensointia tautia aiheuttavien varianttien tunnistamisessa 
potilailla, joilla ei ole geneettistä diagnoosia. Tutkimusaineistomme koostui 
potilaista, joilla on joko progressiivinen myoklonusepilepsia (PME, n=84) tai 
vakava imeväisikäisenä alkava epileptinen oireyhtymä (n=30). Nämä 
oireyhtymät kuuluvat vakavimpien epileptisten oireyhtymien joukkoon ja 
niihin liittyy toistuvia, lääkeresistenttejä kohtauksia ja niillä on huono 
ennuste. Koska aineiston potilaille oli tehty geneettisiä diagnostisia testejä 
ennen tutkimukseen osallistumista, ensisijaisena tavoitteenamme oli 
tunnistaa uusia tautigeenejä ja molekyylimekanismeja näiden oireyhtymien 
taustalla. 
Edistimme tutkimuksen avulla merkittävästi ymmärrystämme näiden 
oireyhtymien molekyyligeneettisestä taustasta. Tunnistimme uuden PME-
alatyypin ja kaksi uutta autosomaalisesti peittyvästi periytyvää 
imeväisikäisten vakavaa enkefalopatiaa, joista toisen kohdalla vaaditaan vielä 
lisäpotilaiden tunnistamista varmistuaksemme havaitsemiemme varianttien 
patogeenisyydestä. Lisäksi laajensimme aiemmin tunnistettujen tautigeenien 
genotyyppi- ja fenotyyppikirjoa. Nämä kolme uutta tautigeeniä edustavat 
kolmea eri molekulaarista mekanismia, jotka yhdessä lisäävät tietoa 
epilepsioiden taustalla olevista tekijöistä. 
Väitöskirjan ensimmäisessä osatyössä tunnistamamme uusi PME-
alatyyppi aiheutuu heterotsygoottisesta missense-variantista c.959G>A 
(p.Arg320His) geenissä KCNC1. Tämä muutos on 11 potilaalla (13 %; eivät 
toisilleen sukua) PME-eksomisekvensointiaineistossa. Alkuperäisen 
löydöksen jälkeen olemme tunnistaneet kuusi lisäpotilasta. KCNC1 koodaa 
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kaliumionikanavaa KV3.1, jolla on keskushermostossa tärkeä tehtävä 
aktiopotentiaalien muodostamisessa. Tunnistamamme mutaatio tässä 
geenissä vahingoittaa kanavan kykyä siirtää kaliumioneita solukalvon läpi. 
Mutaatio on niin kutsuttu de novo –mutaatio eli se on uusi muutos, joka ei 
ole periytynyt vanhemmilta. Arvioimamme mutaatiotaajuuden perusteella 
tämä mutaatio KCNC1-geenissä aiheuttaa PME:n sadoilla potilailla 
maailmanlaajuisesti. 
Toisessa osatyössä tunnistimme viidessä perheessä yhteensä yhdeksällä 
potilaalla yhdistelmäheterotsygootit UBA5-geenin variantit, jotka aiheuttavat 
imeväisikäisenä ilmenevän oireyhtymän. Tämä oireyhtymä ilmenee aluksi 
ärtyvyytenä, ja muita myöhemmin esiintyviä oireita ovat epileptiset 
kohtaukset, dystoniset liikkeet, älyllinen kehitysvamma ja pienipäisyys. 
UBA5 on UFM1-proteiinia aktivoiva entsyymi. UFM1 on pieni ubikitiinin 
kaltainen proteiini, joka kiinnitetään sen kohdeproteiineihin entsyymien 
katalysoimien reaktioiden kautta. UFM1-kaskadin tehtävä soluissa on 
suurelta osin tuntematon. Funktionaaliset kokeemme viittaavat siihen, että 
tunnistamamme UBA5-variantit vähentävät UBA5:n entsymaattista 
aktiivisuutta. UBA5-potilaiden oireet ja löydökset tutkimallamme Ufm1-
hiirimallilla osoittavat, että UFM1-kaskadi on välttämätön keskushermoston 
kehittymiselle ja toiminnalle. 
Kolmannessa osatyössä tunnistimme yhdistelmäheterotsygoottiset 
variantit ADAM22-geenissä todennäköisenä aiheuttajana potilaan 
imeväisikäisenä alkaneelle etenevälle enkefalopatialle, johon liittyy 
epileptisiä kohtauksia ja aivokuoren atrofiaa. ADAM22-proteiini toimii 
LGI1:n reseptorina ja osoitimme tutkimuksessa, että tunnistamamme 
variantit estävät ADAM22-proteiinin ja LGI1:n välisen interaktion. LGI1-
ADAM22 –kompleksi on antiepileptinen tekijä, joka säätelee synaptista 
transmissiota läpi elämän. Näiden proteiinien tärkeää tehtävää korostaa se, 
että Lgi1- ja Adam22-poistogeeniset hiiret kärsivät epileptisistä kohtauksista 
ja kuolevat 2-3 viikkoa syntymänsä jälkeen. Autosomaalisesti vallitsevasti 
periytyvät variantit LGI1-geenissä aiheuttavat epilepsiaa ihmisellä. Vakavasta 
epileptisestä oireyhtymästä kärsivällä potilaalla tunnistamamme proteiinin 
toiminnan estävät, peittyvästi periytyvät variantit ADAM22-geenissä 
viittaavat siihen, että myös ADAM22 kytkeytyy epilepsiaan ihmisellä. Tämän 
kytköksen vahvistaminen edellyttää lisäpotilaiden tunnistamista. 
Kokonaisuudessaan tämä väitöstutkimus osoittaa eksomisekvensoinnin 
tehokkuuden tautia aiheuttavien varianttien tunnistamisessa 
heterogeenisissä potilaskohorteissa, joille on tehty aiempia diagnostisia 
testejä. Löydöksemme edistävät näiden epileptisten oireyhtymien 
diagnostiikkaa, lisäävät tietoa niiden taustalla olevista 
molekyylimekanismeista ja mahdollisesti auttavat kehittämään uusia 
hoitokeinoja. Perheille diagnoosin saaminen merkitsee myös sairauden 
aiheuttajaan liittyneen epätietoisuuden ja turhautuneisuuden päättymistä ja 
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The pace of technological advances in the field of genetics during the past 
decade is unrivalled in almost any other sector in science. The new 
sequencing technologies allow the characterisation of the human genome 
and its variation in the highest detail and in large numbers of individuals 
with relatively low price. Given that the majority of human disorders bear a 
genetic component, it has generated a lot of hope and hype that increased 
understanding of the disease-associated genetic variation would translate 
into clinical applications where diagnosis and treatments would be more 
efficient and accurate. Personalised medicine is the buzzword that underlies 
the overall aim of the current medical research to be able to identify the 
causal molecular mechanisms in each individual and offer tailored 
treatments based on the findings.  
Rare diseases have been on the front line of reaching individual-level 
molecular diagnoses. This is largely due to their less complex genetic 
architecture with genetic defects occurring mostly in single genes only. While 
many genes underlying rare diseases were identified using traditional 
approaches, latest sequencing technologies have made it possible to solve 
cases that were a challenge to earlier methods and thus boosted the gene 
discovery substantially (Boycott et al. 2013). However, there is still much 
work to do to achieve complete understanding of the genetic basis of rare 
diseases; the underlying genetic defects remain to be characterised in 
approximately half of the 7,000 rare diseases with genetic origin (Chong et 
al. 2015). The goal to provide targeted therapies in these diseases is even 
further, since only a minority of the rare diseases have a specific drug used in 
the treatment. It is important to achieve these goals in rare diseases; they are 
often severe and life threatening and even though individually rare, they 
collectively affect more than 5% of the population and thus represent a major 
socio-economic burden (Chong et al. 2015). 
Epilepsies, which are a group of diseases characterised by recurrent 
epileptic seizures due to aberrant brain activity, represent one of the clinical 
entities of which aetiology has remained largely uncharacterised before the 
recent advances in the genetic and neurobiological research (Noebels 2015; 
Staley 2015). Considering the fact that epilepsies were long regarded as 
magical or divine diseases, it is fascinating that genetic studies of epilepsies 
are now actually one of the greatest success stories in terms of the number of 
new gene discoveries (Myers and Mefford 2015). While majority of the 
epilepsies remain genetically unsolved, identification of the underlying 
genetic defects in many forms of epilepsies has finally provided 
comprehensive insight on what molecular mechanisms trigger seizure 
activity in the brain. 
In this study, we utilised modern sequencing technologies to dissect the 
genetic basis of unexplained, rare syndromes with epilepsy. Our focus was on 
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the most devastating forms of epileptic syndromes that occur in early life, do 
not respond to treatments and where symptoms get worse over time. 
Identification of the genetic cause of the disease in these patients would end 
the ‘diagnostic odyssey’, which typically involves years of frustration, 
numbers of medical appointments and unsuccessful diagnostic tests. 
Moreover, establishing the genetic diagnosis is the first step on the way to 
find targeted therapies to the disease. 
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2 REVIEW OF THE LITERATURE 
2.1 Variation in the human genome 
The human genome comprises of the nuclear and the mitochondrial genome. 
The former consists of over 3 billion base pairs (bp), either adenosine (A) 
pairing with thymine (T) or cytosine (C) with guanine (G). In the nuclear 
genome, the letters of DNA are subdivided into 22 pairs of autosomes and 
one pair of sex chromosomes. The mitochondrial genome is only 16.6 
kilobases (kb) in size but is present in multiple copies in each mitochondrion. 
Genes are functional elements of the genome. Recent estimates suggest that 
the human genome contains approximately 19,000-20,500 protein-coding 
genes (Clamp et al. 2007; Ezkurdia et al. 2014). However, splicing of 
messenger RNA, which shuffles the coding parts of the genes before 
translation into amino acid sequence, and post-translational modifications of 
proteins, increase the true number of unique protein molecules present in 
cells to a many folds higher level. In addition, the human genome contains 
RNA genes, which possess information of a wide array of functional RNA 
elements, many of which have only recently been discovered. 
Together with environmental factors, genetic information embedded in 
the human genome determines the characteristics of each individual. 
Variation in the DNA sequence underlies traits, such as height and eye 
colour, but also disorders. A major step towards a better understanding of 
the role genetics in human health and disease was completion of the 
sequence of the human genome over a decade ago (International Human 
Genome Sequencing Consortium 2001; Venter et al. 2001; International 
Human Genome Sequencing Consortium 2004). The main product of these 
efforts was the reference genome, to which all newly generated sequence data 
is compared. After solving the sequence of the human genome, a number of 
large-scale genotyping and sequencing efforts have generated publicly 
available catalogues of all types of genetic variation across various human 
populations (e.g., International HapMap Consortium 2003; The 1000 
Genomes Consortium 2010). This information has provided us basic 
information of the nature of the genetic variation within and between 
populations. Importantly, the generated data are invaluable in analysis of the 
genetic basis of both common and rare diseases, since they help us to 
understand which fraction of the variation is common and likely benign and 
which variation may be associated with disease. 
Mutations are permanent changes in the DNA sequence of the genome 
and thus are the source of genetic variation. Differences between the 
nucleotide sequence of any newly generated genetic data and that in the 
reference genome can be reported as genetic variants. Genetic variation 
ranges from single nucleotide level changes to gains and losses of whole 
chromosomes. Single-nucleotide variants (SNVs) are changes of one DNA 
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letter to another. Small insertions and deletions (indels) are small (<50bp) 
gains or loss of genetic material. Copy-number variants (CNVs) in turn are 
larger scale duplications or deletions of sections of DNA. Other forms of 
structural variants include inversions and translocations.  
Numerically SNVs and indels are most abundant, but CNVs affect a bigger 
number of base pairs (The 1000 Genomes Consortium 2010; Campbell and 
Eichler 2013). Small-scale changes in the genome can arise due to 
spontaneous mutations (e.g. errors in DNA replication) or induced mutations 
(exposure to external mutagens such as ultraviolet radiation). Normally these 
errors are repaired by dedicated molecular pathways, but failures in these 
processes lead to permanent sequence variants that can be transmitted to 
next cell generations, if they occur in somatic cells, or to offspring, if they 
take place in germline cells. CNVs are mostly caused by recombination 
between mispaired sequences during meiosis (Campbell and Eichler 2013). 
Mutations do not occur evenly across the genome. There are so called 
mutation hotspots in which mutations take place more often. For example, 
CG-dinucleotides (CpG sites) are more prone to C to T transitions than other 
nucleotide pairs: the estimated rate of germline base substitutions is 1.210-8 
per base per generation, equalling to an average of 63 new mutations per 
person, but in CpG sites, the rate is 1.1210-7 (Kong et al. 2012). Importantly, 
germline mutations are mostly of paternal origin (Kong et al. 2012). 
2.2 Genetic variation in human disease 
Each human genome contains ~4 million SNVs and indels, of which ~25,000 
occur in protein coding regions (The 1000 Genomes Consortium 2012). 
Altogether, over 100 million variant sites have been catalogued in dbSNP, a 
database for human sequence variation. Already several decades ago it was 
hypothesized that most of the genetic variation within and across species are 
neutral and does not have a dramatic evolutionary effect (Kimura 1968). 
Along this line, recent data from genome sequencing projects have shown 
that the human genome can tolerate a substantial degree of variation without 
any apparent pathogenic effect. For example, a typical human genome 
contains over 100 rare loss-of-function variants that are predicted to disrupt 
the gene function and a subset of them even affect both copies of the gene 
(The 1000 Genomes Consortium 2010; Sulem et al. 2015). Highlighting the 
widespread and dense nature of genomic variation, sequencing of the 
protein-coding elements of the genome (exome) in 60,000 individuals as 
part of Exome Aggregation Consortium (ExAC), showed that there is a 
variant in every 8 bp in at least one individual of the sample set (Lek et al. 
2015).  
However, not every kind of genetic variation is neutral or without 
phenotypic effect. Some variants increase susceptibility to certain disorders 
or even directly cause them. Moreover, some variants are evolutionary 
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advantageous and are subjected to positive selection. In gene level, genes that 
have, for example, highly important function in the embryonic development 
tolerate only a little variation in the amino acid sequence, whereas some 
other genes, such as those encoding olfactory receptors are more likely to be 
nonessential and can more often be completely knocked out without obvious 
effect (Sulem et al. 2015). Given that proteins represent important functional 
elements of the cell, it is therefore no surprise that much of the deleterious 
variation that is eliminated by negative, purifying selection resides within the 
exome. This can be seen in the sequence data from the 1000 genomes 
project, which showed that gene exons have 50% less genetic diversity 
compared to intronic regions (The 1000 Genomes Consortium 2010). 
Particularly during the recent years, however, the importance of variation in 
noncoding regions of the genome for human disease has also been noted. For 
example, many variants that predispose to multifactorial diseases are located 
in regulatory regions of genes and affect the levels of gene expression (Albert 
and Kruglyak 2015). Noncoding variation can also have a dramatic effect on 
gene function, for example by disrupting splicing (Epstein 2009). 
Genetic variants can be classified based on their consequence on the 
function of the gene product. Loss-of-function variants result in abolished 
function. Hypomorphic variants are a subtype of this class and cause a partial 
loss of function. Dominant-negative variants have the ability to disrupt the 
function of the wild-type allele. Gain-of-function variants result in an 
enhanced or altered function, for example, an ion channel remains always 
open. More specifically, variants can be classified based on their effect on 
protein sequence. Silent or synonymous variants do not change the amino 
acid sequence, whereas missense variants cause a substitution of an amino 
acid residue to another. Variants that are commonly categorised under the 
name of loss-of-function variants include splice site (disrupt splicing), 
nonsense (premature stop codon) and frameshift indel (disrupt reading 
frame) variants. However, these variants do not necessarily always cause loss 
of function of a gene, for example, when a nonsense mutation occurs in the 
very end of the coding sequence of the gene. On the other hand, one needs to 
bear in mind that also noncoding, missense or synonymous variants can have 
a complete loss-of-function effect if, for example, a missense change disrupts 
a catalytically active residue or a synonymous change disrupts splicing. 
2.3 Genetics of rare diseases 
By European Union definition, rare diseases have a prevalence less than 1 in 
2000 in the population (European Comission 2016). It is difficult to estimate 
precisely the number of rare diseases but a commonly cited figure is around 
6,000-7,000 (Boycott et al. 2013; Chong et al. 2015). In aggregate, rare 
diseases are not uncommon. As many as 25 million of the US population are 
affected by a rare disease and globally this number reaches 350 million 
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(Chong et al. 2015; Global Genes 2016). Rare diseases are often severe, 
chronic and without an effective treatment. Moreover, their diagnosis is 
challenging due to a number of factors, such as their rarity (clinicians may 
not have ever seen a patient with that condition) and clinical overlap with 
other more common ailments. Consequently, a substantial proportion of 
affected individuals receive an incorrect diagnosis initially and getting the 
correct diagnosis may take several years (average 4.8 years) or in the worst 
case it is never reached (Shire 2016). Because of the strong genetic 
component underlying most rare diseases, it is important to utilise genetic 
technologies to improve the currently suboptimal diagnosing of rare diseases. 
Getting an accurate diagnosis quickly is important for a number of reasons. 
First, it reduces emotional toll of the patient and family of not knowing what 
causes the severe illness and assists family counselling when mode of 
inheritance is known. Knowing the specific cause may assist selecting 
optimal treatments and give insight on prognosis. Moreover, it eliminates 
need for unnecessary diagnostic tests involving numerous medical 
appointments and high costs. Finally, with the diagnosis the family can be in 
contact with others who are dealing with the same disease and seek peer 
support.  
Rare genetic diseases are mostly Mendelian, which means that their 
segregation follows the simple rules of inheritance proposed by Gregor 
Mendel in the 19th century. This is because Mendelian (or monogenic) 
diseases are caused by genetic defects that are typically fully penetrant and 
reside in single genes. In autosomal recessively inherited Mendelian diseases, 
disease develops if deleterious variants affect both copies of the gene. In the 
case of X-linked recessive disorders, males develop a disease if their only 
copy of the X chromosome harbours the variant. Recessive diseases are 
typically caused by loss-of-function or hypomorphic variants. Dominantly 
inherited Mendelian diseases are caused by heterozygous variants that can be 
gain-of-function, loss-of-function or dominant-negative. Dominant disease 
genes where even a heterozygous loss-of-function variant is enough to cause 
a disease are called haploinsufficient because expression from both copies of 
the gene is required for normal cell function. Recent large-scale sequencing 
efforts have been able to pinpoint genes that do not tolerate deleterious 
variation in even one copy of the gene. By looking at the amount of 
deleterious variation (missense, loss-of-function) in exome sequences of the 
general population, researchers have recognised genes that have less 
variation than known estimates on mutation rates would suggest, indicating 
that heterozygous variants in these genes are under stronger negative 
selection (Petrovski et al. 2013; Lek et al. 2015). Indeed, many previously 
known disease genes where heterozygous variants cause a disease rank 
among the least tolerant genes for functional variation.  
In addition to inherited genetic factors, de novo mutations, i.e.  newly 
arising mutations occurring either in parental germline cells or at some point 
after conception, contribute to human diseases. Many rare diseases are so 
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severe that patients cannot reproduce and causal variants are then not 
transmitted to next generations. In these disorders, spontaneously occurring 
de novo mutations and/or recessively inherited variants mostly explain their 
presence in the human population (Veltman and Brunner 2012). Besides 
rare, severe diseases (Vissers et al. 2010), the importance of de novo 
variation in more common and genetically more complex conditions such as 
schizophrenia or autism, has been recently understood (Xu et al. 2011; 
O'Roak et al. 2012; Campbell and Eichler 2013). These observations suggest 
that at least some forms of these complex disorders may be caused, or at least 
contributed, by de novo genetic defects in single genes rather than by 
common variation in multiple genes. 
Somatic mutations are de novo genetic alterations that occur after 
conception in any cell type but germ cells. Consequently, they do not affect 
all but a subset of cells in the body and are not inherited. Their role in human 
disease beyond cancer has only recently started to be acknowledged. For 
example, a variant may be present in a large proportion of neurons, but it 
still missed in genetic testing because it is not present at all or at lower levels 
in peripheral blood, which is typically used as the source of DNA in genetic 
studies. Interestingly, recent studies with access to postmortem samples or 
brain biopsies obtained by surgery have been able to characterise somatic 
variation in the brain and shown that somatic mutations may cause brain 
malformations and epilepsy (Poduri et al. 2013; Lodato et al. 2015). 
The developmental stage when a newly arising mutation occurs has 
important implications regarding family counselling and estimating the 
recurrence risk of diseases caused by de novo alterations (Vadlamudi et al. 
2010; Veltman and Brunner 2012). If the mutation occurs in a single gamete 
or after conception, the recurrence risk of the disease in the family is close to 
0%. However, if the mutation affects some if not all diploid germline cells of 
one of the parents the risk can be up to 50%. At individual level a specific 
recurrence risk is not typically possible to obtain, but deep sequencing of 
parental blood samples for the mutations have shown promise in providing 
more accurate estimates in individual families (Rahbari et al. 2016). On 
average, the recurrence risk of diseases caused by de novo mutations has 
been recently estimated to be approximately 1.3% (Rahbari et al. 2016). 
2.3.1 Traditional and modern techniques of genetics research in 
Mendelian disease 
In addition to the benefits related to the diagnosis and care of the patients, a 
better understanding of the genetic basis of Mendelian disease genes has also 
more general outcomes. Identification of a new disease gene is often 
associated with increased knowledge of the gene function and related cellular 
processes (Boycott et al. 2013). Insight on rare diseases can also enhance our 
understanding of related common, complex disorders (Peltonen et al. 2006). 
It has been estimated that the underlying genes have not yet been identified 
in 50% of all known Mendelian diseases (Boycott et al. 2013; Chong et al. 
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2015) and in addition many new diseases remain to be discovered. It has 
been suggested that the human genome contains up to 7,000-15,000 disease 
genes (Cooper et al. 2010a), so likely many thousands of new gene-
phenotype associations are to be made. This hypothesis is supported by 
findings in the ExAC data where over 3,000 genes are almost completely 
depleted of truncating variants and most of these genes have not been 
associated with human disease (Lek et al. 2015). 
Given their more simple genetic background compared to multifactorial, 
complex conditions, Mendelian diseases have been on the front line of gene 
discovery for long time. Disease gene mapping, i.e., localisation of genes with 
disease-causing variants, initiated in 1980s with the discovery of the gene 
underlying Huntington’s disease (Gusella et al. 1983). For the next two 
decades, gene discovery studies relied primarily on genome-wide linkage 
analysis where disease genes were mapped using polymorphic genetic 
markers that are in linkage with the disease gene locus, i.e. the marker and 
the gene locus segregate together. Other methods used successfully include 
karyotyping and homozygosity mapping (Gilissen et al. 2011). While these 
methods allowed identification of numerous disease loci, the genetic findings 
were mainly limited to familial diseases that were clinically distinguishable. 
Moreover, disease gene mapping studies in isolated populations, such as 
Finland, were largely successful, since these studies benefited from the 
reduced genetic heterogeneity resulting from genetic bottlenecks in the early 
phases of population history (Peltonen et al. 1999). Traditional genetic 
methods were poor in dissecting the genetic background of complex diseases 
because the effect sizes of the underlying genetic factors are small compared 
to Mendelian diseases and also because the traditional methods do not 
tolerate high levels of genetic or phenotypic heterogeneity (Baron 2001). 
The gold-standard method for DNA sequencing was for many years the 
dideoxy chain-termination method initially developed by Frederick Sanger in 
the 1970s (Sanger et al. 1977). For example, the first human genome was 
sequenced using this technology that is usually called ‘Sanger sequencing’. 
However, the capacity of Sanger sequencing is not sufficient for high-
throughput genome-level sequencing, illustrated by the $3 billion budget of 
sequencing the first human genome (Wetterstrand 2016). Still, Sanger 
sequencing is widely used but its applications are limited to small-scale tasks 
such as confirmation of variants identified using other methods.  
In 2005, the first commercial sequencing machine of the ‘next-generation 
sequencing’ (NGS) era was introduced. NGS machines are able to generate 
low-cost, high-throughput sequence data. Their basic principle is to sequence 
clonally amplified or single molecule templates in massively parallel fashion 
(Rehm et al. 2013). There are a number of chemistries underlying various 
NGS technologies but one of the most widely used is the sequencing-by-
synthesis method originally developed at Solexa, which was later acquired by 
Illumina. This method utilizes fluorescently labelled nucleotides that are 
added one-by-one by a DNA polymerase to amplify single-stranded DNA 
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molecules attached to the surface of a flow cell (Mardis 2013). An image is 
taken of each labelled nucleotide that is incorporated to the DNA molecule. 
Based on the image, a computer determines the correct base at each position, 
and the base calls are used to deduce the nucleotide sequence. This method 
produces sequence reads that are relatively short, 50-3oo bp in length, which 
makes it more challenging to align the sequence reads to the reference 
genome and limits its usability to detect for example long repeat 
polymorphisms and complex genomic rearrangements. However, the issues 
caused by short read length can be reduced by using paired-end sequencing 
where each DNA molecule is sequenced from both directions.  
Illustrating the rapid progress of NGS technologies, we have reached a 
stage where the actual sequencing is not anymore the rate-limiting step in 
genomics research. The production cost of sequencing one human genome 
can now be as low as $1,000 in large-scale sequencing facilities (downstream 
informatics costs not included in the figure), and instead of years that it took 
to sequence the first human genome, it takes now less than a week 
(Wetterstrand 2016). Now, the more costly and challenging part is the 
storage, processing and interpretation of the massive amount of genetic 
information that is now being generated at the rate of thousands and 
thousands of whole-exomes and genomes per year. 
2.3.2 Gene discovery and diagnostics in the next generation 
sequencing era 
The introduction of NGS technologies has had important implications on the 
gene discovery in human diseases. Instead of using genetic markers as 
proxies to the disease-causing variants, genetic variation can be now detected 
directly for many individuals in parallel. Indeed, the modern approaches 
have boosted gene discovery in Mendelian diseases (Boycott et al. 2013). It is 
now possible to decipher the genetic basis of diseases showing clinical and 
genetic heterogeneity and that of diseases that are mostly sporadic, which 
was challenging with traditional methods.  
One of the main advantages of NGS-based methods in genetic studies is 
that they enable utilisation of ‘genotype-first’ or ‘reverse phenotyping’ 
approach (Figure 1). It means that the usual diagnostic approach relying 
primarily on the clinical features of the patient can be reversed and the 
precise diagnosis can be established based on the genetic findings (Stessman 
et al. 2014; de Goede et al. 2016). This is based on the ability of NGS 
technologies to examine genetic variation in a large number of individuals in 
an exome- or genome-wide manner without need for a priori hypotheses 
regarding the biological function of disease genes. The following example 
illustrates the benefits of the genotype-first approach: let us imagine a study 
cohort of 100 cases, who belong to a genetically and phenotypically 
heterogeneous disease entity. With NGS, one could recognise that 10 cases of 
the cohort have pathogenic variants in the same gene, so they have the same 
molecular diagnosis. However, if diagnosis had to rely solely on clinical 
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symptoms, in the absence of specific symptoms, it could have been virtually 
impossible to recognise the etiological subgroups. Furthermore, with 
traditional genetic methods it would have been difficult to identify the 10 
cases with genetically identical disease because of the genetic heterogeneity 
in the cohort. One of the advantages of the genotype-first approach is also 
that it can be used to make a specific diagnosis in cases where extensive 
clinical phenotyping is not possible (Shi et al. 2014). Furthermore, 
hypothesis-free, genome-wide approaches allow expansion of the phenotypic 
spectrum of already known disease genes. For example, TBC1D24 is a gene 
that was originally linked to epilepsy, but it has since reported also in 
deafness and a multi-organ syndrome (Falace et al. 2010; Campeau et al. 
2014; Rehman et al. 2014).  
 
Figure 1 Genetic diagnostics before and during the next-generation sequencing 
era. The figure illustrates how next-generation sequencing (NGS) methods, whole-exome 
sequencing (WES) and whole-genome sequencing in particular (WGS; see below section 
2.3.3), have the ability to fasten the diagnostic process of rare diseases and increase the 
proportion of genetically diagnosed patients. Line and arrow width indicates the proportion of 
patients falling into that category.  
2.3.3 Next-generation sequencing applications in gene discovery and 
diagnostics of rare diseases 
There are three main NGS-based applications in human genetics: gene 
panels, whole-exome sequencing (WES) and whole-genome sequencing 
(WGS) (Table 1).  
In gene-panel sequencing, a selected set of genes, ranging from one to 
hundreds of genes, are sequenced. Selected genes are usually those where 
pathogenic variants have been previously reported for the disease entity in 
question. Typically, the coding regions of the genes are targeted. This 
approach suits well to diagnostic applications when the clinical phenotype 
suggests a specific genetic disorder with known disease gene(s) so it is more 
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cost-efficient to do targeted sequencing in few genes. Moreover, gene panels 
can be a cost-efficient method to screen a replication cohort for variants in 
candidate genes identified in a discovery sample set (e.g., D'Alessandro et al. 
2015). It is also a practical solution when extremely high sequencing 
coverage is needed to target certain clinically relevant genes, for instance, in 
tumour sequencing where somatic mutations may occur at low levels 
(Tripathy et al. 2014). The negative side of the gene panel approach is 
obviously that it cannot be used to identify new disease genes, unless one 
selects candidate genes to the panel based, for example, on function (Carvill 
et al. 2013a; Syrbe et al. 2015). 
Table 1. Comparison of next-generation sequencing applications.  
Property Gene panels WES WGS 
Number of genes covered 1-500 20,000 20,000 
Bases covered Variable ~50 Mb ~3Gb 
Typical mean sequencing coverage >100 60-120 30-60 
Completeness of target region 
coverage ++(+) +(+) ++(+) 
Screening of known genetic causes +++ ++ ++ 
Identification of new genes - ++ +++ 
Detection of noncoding variants - - +++ 
Detection of CNVs and other 
structural variants - + +++ 
Cost ++ + - 
WES, whole-exome sequencing; WGS, whole-genome sequencing; Mb, 
megabases; Gb, gigabases; CNV, copy number variant. 
Plus and minus symbols are used to score the utility of the different NGS 
methods in various categories. 
 
When one aims to discover new gene-disease associations, a more 
extensive approach targeting all genes is required (Rehm et al. 2013). 
Exome- or genome-wide sequencing may also be selected if 1) gene-panel 
testing is negative, 2) the phenotype of the patient is unspecific and selecting 
a correct gene panel is demanding, or 3) if there are hundreds of genes 
underlying the disorder in question, such as intellectual disability.  
As mentioned earlier, majority of variants causing Mendelian diseases 
reside within the exome (Chong et al. 2015). Therefore, during the past few 
years the most common approach to identify novel disease-causing variants 
has been to perform WES where the sequencing library is created using RNA 
or DNA bait probes to designed capture exonic and splice site regions 
(Figure 2). Since the exome constitutes of only about 1.5% of the whole 
genome, WES is a cost-efficient method ($500-1500) to tackle the most 
relevant parts of the genome in terms of potentially deleterious variation. 
The first application of WES in gene discovery was published in 2009 (Ng et 
al. 2010). Thereafter, WES has proven to be successful to dissect the genetic 
basis of Mendelian disorders of all possible mode of inheritance (reviewed by 
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Boycott et al. 2013). The typical diagnostic yield of exome sequencing in 
large-scale studies of Mendelian disorders is typically around 25-30%, which 
is higher compared to conventional genomic assays such as karyotyping and 
CNV analysis with microarrays (reviewed by Chong et al. 2015). However, 
the true diagnostic yield of WES is likely higher because many of the study 
subjects of the current WES studies have already underwent other genetic 
testing prior to the study. Indeed, in a recent study where WES was used as a 
first-tier genetic test in infants with suspected Mendelian diseases, diagnostic 
yield was 58%, whereas application of single- or multigene panels to the 
same individuals led to genetic diagnosis in only 14% of cases (Stark et al. 
2016). WES has also contributed to the understanding of cancer and other 
complex conditions (Rabbani et al. 2014; Van Allen et al. 2014). However, 
because individual genetic factors have only a minor effect on susceptibility 
of common disorders, large sample sets of thousands of individuals are 
required in order to identify statistically significant genetic associations in 
complex conditions (Do et al. 2012). This requirement has hindered utility of 
WES and other NGS applications in common, complex diseases. In general, 
one of the limitations of WES is that it does not typically cover all target 
regions with adequate sequencing depth (5-10%), and consequently clinically 
important variants may be missed. GC-rich regions are in particular 
challenging regions to capture (Asan et al. 2011). However, with most recent 
versions of exome capture kits, this issue has become less substantial 
(Lelieveld et al. 2015). While WES can be used to detect CNVs (Fromer et al. 
2012; Poultney et al. 2013), the sensitivity and resolution is lower than in 




Figure 2 Whole-exome target capture protocol. This protocol applies to exome 
capture methods based on in-solution hybridisation, which is the most widely used 
approach. First, genomic DNA is fragmented, and adapters (yellow and green) are ligated to 
DNA fragments (blue colour indicates exonic regions, red noncoding). Next, biotinylated 
RNA baits designed to bind to exonic regions are hybridised with the DNA library. 
Streptavidin-coated magnetic beads attach to biotin on the probes and the complexes are 
pulled down using magnets. Finally, beads are washed away, RNA digested and exonic 
DNA subjected to sequencing. 
With WGS, it is possible to detect virtually all SNVs, indels and CNVs in 
one assay, which separates it from other genetic tools. WGS may even cover 
variants in exonic regions better than WES because it provides more uniform 
sequencing coverage and more balanced allele ratios (Meynert et al. 2014; 
Lelieveld et al. 2015). The caveat of WGS, and other NGS technologies that 
rely on short-read sequencing technologies, is that they cannot detect repeat 
expansions, which cause, for example, many neurodegenerative diseases 
(Everett and Wood 2004). Its usage has also been prohibited by high cost (2-
4 times more than WES without taking additional computational burden into 
account (Lelieveld et al. 2015)), but as described above, with the rapid 
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decline in costs it is becoming now a more feasible application in Mendelian 
genetics (Gilissen et al. 2014; Taylor et al. 2015; Willig et al. 2015; 
Stavropoulos et al. 2016). The utility of WGS is also affected by the limited 
knowledge about the functional consequence of variants outside the coding 
region. Tools aiming to surmount this issue have, however, been developed 
recently (Kircher et al. 2014; Ionita-Laza et al. 2016). 
Altogether, recent studies have demonstrated that WES and more 
recently WGS provide a powerful method to diagnose genetic disorders. The 
cost of a single run of WES, and in particular WGS, is still higher than 
conventional methods, such as gene panels or microarrays used in CNV 
detection. However, they are likely to be more cost-efficient overall because 
they have a higher diagnostic yield, reduce the time to get a diagnosis and 
may also detect secondary (incidental) findings with clinical relevance 
(Soden et al. 2014; Stavropoulos et al. 2016). The clinical utility of WES and 
WGS is highly dependent on which phenotype is in question. These methods 
are powerful in, for example, severe neurodevelopmental disorders but their 
diagnostic yield may be much lower in other severe but apparently 
genetically more complex conditions such as some forms of immunological 
disorders (Taylor et al. 2015). 
2.3.4 Processing of next-generation sequencing data 
2.3.4.1 Sequence read processing 
An analysis pipeline of NGS data aims to transfer the raw sequence data to a 
high-quality set of annotated variant calls, while doing quality control checks 
for the data at multiple steps along the analysis process. Given the huge 
amount of data produced, its processing requires extensive computational 
infrastructure and bioinformatics expertise. There is not a single correct way 
to do the data processing, and because of constant method development in 
the field, there is now a wide range of public and in-house tools for each step 
of the pipeline. Broad Institute’s Genome Analysis Toolkit (GATK) has 
become, however, the most widely used software package, owing to its active 
development, comprehensive documentation and user support.  
The principal steps of NGS data analysis pipeline are presented in Figure 
3. NGS technologies produce tens of millions of short sequence reads per one 
exome. The first step after base calling, generation and quality control of raw 
sequence reads is to do alignment, i.e., to determine the most likely position 
of the sequence reads in the reference genome (Flicek and Birney 2009). The 
most commonly used methods for short-read sequence alignment include 
BWA and Bowtie, which are computationally efficient and fast (Langmead et 
al. 2009; Li and Durbin 2009). For some sequence reads, it is difficult or 
even impossible to determine the correct location because the same or highly 
similar sequence is present in two or more locations in the genome. These 
regions include segmental duplications which are genomic sites 1-400 kb in 
length and share >90% sequence identity (Sharp et al. 2005). A mapping 
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quality score, describing the reliability of the real alignment, is given to each 
read after alignment. Variant calls in reads with low mapping quality are 
more likely to be false positives. After alignment, it is important to mark 
reads that have equal start and end positions. These read duplicates arise 
typically in polymerase chain reaction amplification of DNA as part of 
sequencing library preparation (Xu et al. 2012). If the duplicate reads are not 
flagged, it can bias variant detection.  
At this point, the quality of the aligned sequencing data can be assessed. 
In the case of WES, one can for example check what proportion of reads 
mapped to the targeted region. If it is low, it may indicate errors in the target 
enrichment process in the laboratory. Moreover, it is important to assess the 
sequencing coverage across the target regions. Samples with low coverage 
may be resequenced to produce enough data for adequate variant detection. 
The desired sequencing coverage depends on the application, with clinical 
WES in particular aiming to have as little gaps in the exome as possible. 
Because better coverage equals to higher cost, one needs to balance between 
the coverage and number of samples that the budget allows to sequence. In 
typical WES studies, mean sequence coverage is 60-150 reads per base (60-
150), but because the coverage is not uniform in WES, only ~80-95% of 
target regions are typically covered with 20 (a commonly used threshold for 
high-confidence variant detection) when having above-mentioned mean 
coverage values. Next steps in the pipeline recommended by GATK are the 
realignment of reads near indel sites and recalibration of base quality scores, 
which both improve quality of the data and allow better quality variant 
detection.  
 
Figure 3 Flow chart of next-generation sequencing data production and 
bioinformatic processing. 
2.3.4.2 Variant detection 
Given the importance of obtaining high-quality variant information from 
sequencing data, variant detection, or variant calling, has been under active 
method development. Several variant calling tools have been developed to 
SNV and indel calling, the most commonly used being GATK and samtools 
(Li et al. 2009; McKenna et al. 2010; DePristo et al. 2011). Methods to detect 
CNVs from WES data have been discussed by Tan et al. (2014). When 
selecting the variant caller and parameters for variant calling and quality 
control, one should always test different approaches to obtain best results for 
own sequencing data. The need for careful assessment of different variant 
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calling protocols is highlighted by the observed disconcordance between 
various variant calling pipelines (O'Rawe et al. 2013). The most important 
factors determining the reliability of variant calls is the sequencing depth and 
quality of base calls. The more high quality sequence reads cover a variant 
site, the more confident variant calls and genotypes (heterozygous or 
homozygous) can be obtained. While there has been significant method 
development, indels are still harder to call reliably compared to SNVs (Fang 
et al. 2014). 
There are two main approaches to perform variant calling. The traditional 
method is to do variant calling separately for each sample. An alternative, 
more recent approach, which is implement in GATK UnifiedGenotyper and 
HaplotypeCaller algorithms, is to do variant calling jointly for multiple 
samples in the same analysis (Liu et al. 2013; Lek et al. 2015; GATK Best 
Practices 2016a). The power of the joint approach is that when combining 
data for each locus from multiple samples, the variant caller has more 
confidence to determine whether the signal is likely to be a true variant or an 
artefact (GATK Best Practices 2016a). In other words, the sensitivity to 
identify low-frequency variant is better and also false positive variants are 
more confidently detected. Singleton variants, i.e., variants that occur only in 
one case of the sample set, do not, however, necessarily benefit from the joint 
calling approach and single-sample calling methods may sometimes provide 
better sensitivity (GATK Best Practices 2016a). Performing joint calling is 
important when for example variant data of family members is analysed. 
When doing single-sample variant calling, incomplete information of the 
segregation of the variant may be obtained, if, for example, a true variant in 
one of the individuals is missed because the signal quality happened to be 
low. Joint analysis would in turn provide genotypes that are more reliable for 
each member of the family.  
Quality-based assessment of generated variant calls is an important task, 
since raw variant calls contain many false positives. The goal is to do quality-
based filtering so that the number of real variants in the filtered data is 
maximised, while removing as high proportion of artefacts as possible. A 
traditional method is to set numeric filtering thresholds for several quality-
related variant annotation scores, this is so called hard-filtering (GATK Best 
Practices 2016b). For example, in a very simplified scenario one could filter 
out variants that have at least one of the following two possible indicators of 
low quality: 1) strand bias, i.e, alternate allele occurs more often in either 
positive or negative strand and 2) mapping quality value is low, for example, 
<20. However, with this method true variants can be missed just because one 
of the annotations showed indication of low quality even though all the 
others suggested it is a high-quality variant. On the other hand, to avoid 
losing true variants one may need to relax the filtering cut-offs, which can 
lead to increased number of false positives. An alternative approach, which 
can be used as part of GATK pipeline, aims to bypass these issues by 
integrating information from the individual quality-based annotations to one 
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recalibrated quality score (GATK Best Practices 2016b). In this approach, a 
training set consisting of well-established markers is used to pinpoint likely 
true variants from the variant call dataset. This way an annotation profile of a 
good quality variant can be determined. If the annotation profile of a variant 
differs substantially from those likely to be true, it can be filtered out. With 
this method, one can select a desired sensitivity and specificity threshold for 
variant filtering. One can use the newly generated variant quality score to 
find the appropriate balance between selecting all the possible variants while 
accepting to have more false positives or selecting only high-confidence 
variants while risking to lose true variants. 
2.3.4.3 Variant annotation 
After obtaining a reliable set of variant calls, the initial information about the 
variant is the genomic position, the nucleotide level change and the genotype. 
To make use of the data and try to facilitate identification of the causal 
variant(s) (see section 2.3.5), it is necessary to obtain more information 
about each variant, including the consequence (missense, synonymous etc.), 
location (intron or exon, which gene etc.) and frequency (in the general 
population or disease-specific databases). This process is called variant 
annotation. Which annotations are needed depends on the application. 
Widely used annotations in Mendelian genetics are listed in Table 2. The list 
contains both variant- and gene-level annotations that can be utilised in the 
interpretation of the clinical significance of the variant.  
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Table 2. Variant- and gene-level annotations for sequence variants. 
Annotation type Example databases Example annotations 
Variant level   
Consequence VEP, ANNOVAR, SnpEff Missense, intronic 
Gene Ensembl, CCDS, RefSeq SCN1A 
Population allele frequency ExAC, 1000 genomes, EVS 1.5% in Finns in the ExAC 
Clinical variant databases ClinVar, HGMD Pathogenic in ClinVar 
In-house allele frequency In-house variant database 30% (a common variant in 
population or a sequencing 
artefact) 
Evolutionary conservation phyloP, GERP Numerical scores (the higher 
the score, the more 
conserved site) 
In silico deleteriousness 
prediction 
CADD, PolyPhen, SIFT, 
MutationTaster 
Probably damaging (by 
PolyPhen) 
Gene level   
Gene function Uniprot Voltage-gated sodium channel 
Expression GTEx Central nervous system 
Associated disease OMIM Severe myoclonic epilepsy of 
infancy 
VEP, Variant Effect Predictor; CCDS, Consensus coding sequence, ExAC, Exome 
Aggregate Consortium; EVS, Exome Variant Server; HGMD, Human Gene Mutation 
Database; GERP, Genomic Evolutionary Rate Profiling; CADD, Combined Annotation 
Dependent Depletion; SIFT, Sorting Intolerant from Tolerant; GTEx, Genotype-Tissue 
expression; OMIM, Online Mendelian Inheritance in Man 
 
There are multiple software packages that can be used to retrieve most of 
the annotations, one of the most popular ones being Variant Effect Predictor 
(McLaren et al. 2010), ANNOVAR (Wang et al. 2010) and SnpEff (Cingolani 
et al. 2012). These tools are user-friendly and typically accept custom 
annotation sets to be integrated as part of the annotation pipeline. When 
determining the consequence of variants, an important choice to be made is 
the gene annotation set based on which the annotation is done. Of the three 
most widely used gene annotation sets, Ensembl contains the highest 
number of gene transcripts but it includes many of which biological function 
is questionable. RefSeq of the National Center for Biotechnology Information 
(NCBI) is another comprehensive and annotated gene set that is widely used. 
Consensus coding sequence (CCDS) represents most conservative set of 
genes, because it represents a consensus gene set of Ensembl and RefSeq. In 
practice, a single locus may contain multiple overlapping genes and gene 
transcripts and the annotation of a variant may vary depending on the 
transcript. For example, at a given genomic position, a SNV may be 
annotated as intronic but in another transcript the variant encodes a 
missense variant, because it is located in an exon that is not present in the 
first transcript. Typically, the transcript having a variant annotation with the 
most severe predicted consequence is selected while prioritising high quality 
gene transcripts.  
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2.3.5 Analysis and interpretation of sequence data to identify disease-
causing variants and new disease genes 
The appropriate strategy to identify disease-causing variants and novel 
diseases genes in NGS data depends on severity, mode of inheritance and 
prevalence of the disease (Gilissen et al. 2012). In fact, these factors should 
already be taken into consideration when selecting samples that are 
sequenced. The selection process is naturally affected also by available funds 
and availability of DNA specimens. Various study and analysis designs for 
identification of pathogenic variants and novel disease genes from WES or 
WGS data are presented in Figure 4. The whole analysis process is 




Figure 4 Strategies for identification of disease genes in whole-exome or whole-
genome sequencing studies. The figure illustrates suggested sequencing and variant 
analysis strategies for monogenic disorders with different modes of inheritance (A-D). 
Dashed lines indicate individuals whose sequencing would provide powerful reduction in the 
number of candidate variants in the data analysis. Coloured circles below the pedigrees 
indicate types of variants that are analysed in a disease of given inheritance pattern. Stars 
indicate the group of variants that are presumed to contain the disease-causing changes. In 
the panel D is presented two alternative approaches to identify disease genes with de novo 
variants. On the left is presented an overlap approach where the variant data of sporadic 
index cases are filtered for novel heterozygous variants that are not present in population 
databases, and the aim is to identify genes where multiple affected individuals have 
variants. This approach can be successful in disorders with limited genetic heterogeneity 
and may also be applied with other inheritance patterns. On the right is presented a trio 
approach, which is similar to the overlap approach but there complete family trios consisting 
of unaffected parents and an affected child are sequenced to allow direct assessment of de 
novo variants. It is therefore a more powerful strategy. It is also to be noted that in some 
family trios with sporadic patients the underlying pattern of inheritance may also be 
recessive, mitochondrial or even autosomal dominant in the case of incomplete penetrance 
or imprinted genomic loci. Therefore, it is always advisable to use variable strategies in 
disease gene identification studies. Adapted from Boycott et al. (2013) and Gilissen et al. 
(2012). 
2.3.5.1 Filtering of whole-exome sequencing variant data 
Independent of the utilised NGS application, similar considerations 
regarding variant filtering apply. To use WES data as an example, exome bait 
regions, which also contain intronic sequences, contain typically 40,000 
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variants, while actual exonic regions and exon-intron junctions altogether 
have 20,000-25,000 variants. The aim of the variant filtering process is to 
narrow this number down so that identification of the disease-causing 
variant(s) becomes possible (Figure 5). Variant filtering should not be 
considered as an inflexible process with only one correct way to do it. If 
filtering parameters used in the initial round of analysis do not yield likely 
pathogenic variants, one should adjust them, for example, by using other 
assumptions regarding the mode of inheritance. 
 
Figure 5 A typical variant filtering process to identify disease-causing variants 
from whole-exome sequencing data. A filtering protocol is described assuming recessive 
or dominant/de novo inheritance. When filtering for de novo variants, the consequence 
based step can be omitted because the number of resulting variants would be low despite 
including noncoding and synonymous variants. 
One typically included layer in variant filtering is to select changes that 
are likely to affect the protein sequence. Variants that are usually kept are 
missense, nonsense and splice site variants as well as inframe or nonframe 
indels. In this stage, synonymous, intronic and other type of variants outside 
the coding regions are usually removed. However, while vast majority of 
these variants are benign, there are several examples of intronic and 
synonymous variants that are pathogenic because they impair splicing 
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(Eriksson et al. 2003; Wang and Cooper 2007). To assist identification of 
pathogenic noncoding variants, there are now bioinformatic tools that can be 
used for any type of variant to predict their deleteriousness and effect on 
splicing (Desmet et al. 2009; Kircher et al. 2014; Ionita-Laza et al. 2016). 
However, since these tools are still not sensitive nor specific, the initial round 
of analysis is usually done to include only coding variants. 
A filtering step based on the population frequency of the variants removes 
the vast majority of the remaining variants. When aiming to identify the 
genetic cause of a rare Mendelian disease, one can assume that the 
underlying genetic variants are rare or absent in the general population. 
Recently, establishment of comprehensive variant databases, such as ExAC, 
1000 genomes and Exome Variant Server (EVS), has greatly facilitated 
annotation of the population frequency of variants. Therefore, identification 
of variants, which are too common in the population to cause a severe, 
Mendelian disease, has become more straightforward. These databases 
contain exome and/or whole genome variant information of adults without 
severe paediatric diseases. While the databases are a great resource to 
pinpoint variants that are too common to cause a severe, early-onset disease, 
one must take into account that some of the individuals in these datasets may 
have common diseases or will later develop a disease. Therefore, they should 
not be considered to contain individuals who cannot possess disease-causing 
variants of any kind, which has implications for variant interpretation (see 
below). Particular care should be applied when filtering against the NCBI 
dbSNP database, the most comprehensive genome variation portal, because 
it may contain disease-causing variants including those submitted originally 
to the NCBI ClinVar database of clinically-associated variants. When 
performing variant frequency based filtering, it is important to use frequency 
information from the appropriate populations. A given variant may appear 
novel or rare in populations that are included in the commonly used 
databases, but it may in fact be a common polymorphism in the specific 
population where a study subject is originated. This is not an issue for 
individuals of European origin, since those are well represented in reference 
datasets, but populations from developing countries are generally not well 
covered.  
An appropriate allele frequency threshold used in variant filtering 
depends on the assumed pattern of inheritance. When filtering variant data 
under a recessive model, an often-used threshold for allele frequency is 1% 
but also values higher or lower than that appear in the literature. Selection of 
frequency cut-offs is done based on the estimated prevalence of the disease 
but this is often difficult. Therefore, selection of frequency cut-offs is always 
arbitrary and one must be cautious of not selecting too low values since some 
of the recessive diseases, such as cystic fibrosis (Cutting 2015), are caused by 
variants that have relatively high frequencies in the study populations. 
Particularly in isolated populations, the carrier frequencies of severe 
Mendelian diseases can be over 1% (Peltonen et al. 1999). In dominant 
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disorders, selecting the frequency threshold is affected by the prevalence and 
age of onset of the disease as well as the estimated penetrance of the causal 
variant. If the disease is severe and early-onset, one can initially filter out all 
variants present in the population-based variant databases or use a very low 
frequency threshold. However, if the disease is adult-onset and/or variants 
are not suspected to be fully penetrant, i.e. they do not cause the disease in 
all carriers, such as in many forms of epilepsies (e.g., Rosanoff and Ottman 
2008; Dibbens et al. 2013; Ishida et al. 2013), a higher value should be used.  
After filtering the variant data based on the predicted consequence and 
the population frequency of the variants, the next step is to include variants 
that are compatible with the assumed segregation pattern. It is worth noting, 
however, that variant filtering should not be limited on the most obvious 
inheritance model(s). For example, an apparently recessive disease may 
actually be due to heterozygous variants that are germline mosaic in one of 
the parents. In sporadic cases, both de novo and recessive variants should be 
analysed. In familial cases, either dominant or recessive defects (autosomal 
or X-linked) are included depending on the segregation pattern of the disease 
in the family. In consanguineous families, homozygous variants can be 
prioritised, however, even in these families the pathogenic variants can be de 
novo or compound heterozygous (Powis et al. 2016).  
Exome sequencing in as many family members as possible, in addition to 
the index case, facilitates removal of benign variants and identification of the 
disease causing variants, but it is associated with increasing sequencing 
costs. In large pedigrees, a cost-efficient solution is to sequence two as 
distantly related affected individuals as possible and one unaffected relative. 
Direct detection of de novo mutations requires exome sequencing in the 
parents. An alternative but less powerful approach to identify causal de novo 
variants is to filter variant data for novel heterozygous variants and subject 
any candidate variants in known disease genes, for example, to segregation 
analysis in parents. However, if the parental samples are only capillary 
sequenced for one variant, there is a risk that wrong implications regarding 
the segregation pattern are made due to sample mix-up or nonpaternity. 
Therefore, the correct relationship of DNA samples should be checked by, for 
example, genotyping polymorphic genetic loci.  
After filtering variants based on the function and population frequency 
under assumed inheritance model(s), it is worthwhile to use sequence 
visualisation tools, such as Integrative Genomics Viewer, to assess the quality 
of the candidate variants. Despite quality control measures implemented as 
part of the variant calling process, some artefacts typically remain in the 
data.  
2.3.5.2 Interpretation of variant pathogenicity 
Given the complex nature of the genetic variation in the human genome, the 
assessment of variant pathogenicity is often not a simple task. Giving wrong 
information regarding the pathogenicity of a variant or missing the likely 
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genetic cause due to misinterpretation can have dramatic consequences to 
patient care and counselling. Therefore, interpretation of variant 
pathogenicity is a process that should ideally utilise several lines of 
information including genetic, segregation, computational, clinical and 
functional data (Richards et al. 2015).  
To improve the quality of variant interpretation and reporting, guidelines 
for informed and careful assessment of genetic information in clinical setting 
have recently been suggested (MacArthur et al. 2014; Richards et al. 2015). 
American College of Medical Genetics and Genomics (ACMG) has 
established a five-tier scale to describe the pathogenicity of a variant: 
pathogenic, likely pathogenic, variant of unknown significance, likely benign 
and benign (Richards et al. 2015). Each of these categories is accompanied 
with specific criteria that a variant needs to fulfil. These guidelines have 
become widely adopted in clinical laboratories and some of the general 
considerations underlying them are covered here. 
In the simplest scenario in terms of variant interpretation, the sequence 
data of a patient may reveal a variant that has been reported to cause a 
disease in several unrelated individuals in independent publications. If the 
phenotype of the patient and segregation pattern of the variant are 
compatible with those linked to the gene previously, it is straightforward to 
report the variant as pathogenic. A more complex situation occurs when a 
patient is, for example, compound heterozygous for two rare missense 
changes that have not been reported in other patients. If the phenotype of the 
patient has some overlap with that reported previously in patients with same 
disease gene, it is tempting to classify the variants pathogenic or likely 
pathogenic. Considering that there are, for instance, hundreds of epilepsy-
associated genes, one could observe variants just by chance in one of these 
genes. Therefore, in this kind of scenario more evidence to support the 
pathogenicity classification should be obtained. Further support of 
pathogenicity may be obtained from segregation data but in the case of small 
families, this evidence alone is not very strong. To estimate the 
deleteriousness of missense variants, one can utilise computational tools that 
take into account protein structure and domain information as well as 
evolutionary conservation of the variant site. Evolutionarily more conserved 
loci are more likely to be functionally important and that is why these 
residues are generally enriched for disease-causing variation (Cooper et al. 
2010b). However, because the accuracy of these in silico prediction tools is 
currently not ideal, they should be used with caution (Hicks et al. 2011). 
Functional laboratory assays may give insight on the effect of a variant on 
protein function, but for many genes of unknown function or for those where 
an assay has not been developed, this is not a possibility. Furthermore, even 
if an assay exists, it may be costly and laborious, thus hindering its utility in 
everyday clinical testing. Hence, development of high-throughput methods to 
perform functional assessment of a large number of missense variants is a 
major area for further research (Starita et al. 2015). It also important to bear 
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in mind that not all variants with a functional effect are pathogenic 
(MacArthur et al. 2014), because, for example, a cell may tolerate reduced or 
even completely abolished gene function. Therefore, results from functional 
assays should be analysed in relation to those variants known to be both 
functional and pathogenic (e.g. reduction in enzymatic activity at least 40%) 
and to those that are benign (e.g. less than 40% reduction). 
With the emergence of large-scale population variant databases and 
increased knowledge regarding variant interpretation it has become evident 
that many variants initially reported as pathogenic and included in databases 
of clinically-associated variants are actually likely to be benign (MacArthur et 
al. 2014; Lek et al. 2015). In the early years of genetic research the number of 
control samples used was much lower, and now, data in the recently 
established comprehensive population variant databases indicate that many 
variants initially interpreted as pathogenic are actually too prevalent to 
cause, for example, a rare dominantly inherited disease (Minikel et al. 2016). 
Along the same line, because information in the disease variant databases, 
such as ClinVar and Human Gene Mutation Database, is not always curated 
using clinical standards, the pathogenicity of variants should not be assessed 
only based on information retrieved from these resources (Rehm et al. 2013). 
Furthermore, some of the variants that have turned out to be present also in 
healthy individuals may be truly causal but they are just not fully penetrant, 
which poses a major challenge for variant interpretation and reporting 
results to patients and their family members (Minikel et al. 2016). 
The fact that each human exome and genome contains a high amount of 
variation means that the genetic code of each individual has the potential to 
be made to fit a story that would explain the phenotype in question. This 
phenomenon has been termed as ‘narrative potential’ of the human genome 
(Goldstein et al. 2013; MacArthur et al. 2014), and highlights the importance 
of common guidelines for variant interpretation. As with many other clinical 
tests, perfect sensitivity and specificity is difficult to reach in genetic testing, 
but with multilevel and careful assessment of variant pathogenicity, risk of 
misinterpretation is minimised. A recent study showed high disconcordance 
between variant classifications reported by independent genetic laboratories, 
which demonstrates that the challenges regarding variant interpretation 
really need to be addressed (Van Driest et al. 2016). 
Because Mendelian diseases are individually rare and even more so are 
the individual variants underlying them, it is therefore of high importance to 
share clinical and genetic information of patients that are studied in clinical 
genetics laboratories across the world. This assists re-evaluation of the 
pathogenicity of variants of which clinical importance has been initially 
unknown. Identification of additional patients with same variants and same 
symptoms would indicate that the variant is indeed pathogenic. Several 
resources aiming to improve data sharing and our understanding of clinical 
relevance of genetic variants have been established. Web platforms enabling 
sharing of genetic and/or clinical data include ClinVar, DECIPHER, LOVD, 
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and MatchMaker Exchange (Firth et al. 2009; Fokkema et al. 2011; 
Philippakis et al. 2015; Landrum et al. 2016). These efforts are valuable not 
only in the interpretation of variants of a single patient but they are also 
designed to match ‘siloed’ unsolved patient exomes and genomes across 
various laboratories to facilitate identification of new disease genes. 
2.3.5.3 Identification of new disease genes from whole-exome or 
whole-genome sequencing data 
When WES or WGS is performed in a research setting, the main goal is 
usually to identify new disease genes. The basic principle is to identify genes 
that are recurrently mutated in the patient cohort after filtering the variant 
data under one of the inheritance models. When for example de novo 
variants in a single novel disease gene are identified in 12 individuals in a 
phenotypically homogeneous cohort of 15 cases, the establishment of a new 
disease gene is already quite evident based on that observation alone. In less 
extreme scenarios with the disease gene present in the minority of the patient 
cohort, further evidence to support identification of a new disease gene may 
be obtained, as discussed above, using segregation analysis and functional 
assays in cell and animal models, which can confirm with high confidence the 
pathogenic role of the newly identified variants.  
Identification of new disease genes in WES or WGS cohorts can be guided 
by statistical approaches that pinpoint genes, which possess more variants in 
cases than expected. Statistical methods are needed because one can observe 
recurrently mutated genes in large patient cohorts just by chance. For 
example, pathogenicity of newly identified variants is highly uncertain if de 
novo variants in the same gene are observed in two individuals in a cohort of 
500. On average, each individual has ~0.8 de novo mutations that alter the 
protein coding sequence, so in a large WES or WGS sample set this kind of 
event could happen just by chance, in particular in genes with a lengthy 
protein coding region (Kong et al. 2012; MacArthur et al. 2014). To test if 
there is an enrichment of de novo mutations in certain genes in a patient 
cohort, it is now relatively well-established to use statistical approaches to 
demonstrate that in the study sample, damaging de novo mutations 
(missense, loss-of-function) occur more often in a given gene than is 
expected (Samocha et al. 2014). These statistical frameworks take into 
account the length and sequence structure of the gene and estimate what is 
the baseline mutation rate for a given gene in the patient cohort. If the 
number of observed de novo mutations is significantly higher than the 
expected value, it implies a disease-causing role for the gene. Naturally, 
functional studies and/or replication in additional cases are ideally used to 
confirm the pathogenic role of the mutations. This statistical approach has 
been successful in pinpointing new disease genes in large-scale sequencing 
efforts in parent-offspring trios of various genetic disorders (e.g., Epi4K 
Consortium and Epilepsy Phenome/Genome Project 2013; 
EuroEPINOMICS-RES Consortium et al. 2014; The Deciphering 
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Developmental Disorders Study 2015). It is a more challenging task to 
establish a computational framework to identify recessive disease genes in 
WES cohorts primarily consisting of small families with sporadic patients. 
Recently, however, Akawi and colleagues utilised a statistical approach to 
characterise new disease genes where unrelated affected offspring have 
potentially deleterious, recessively inherited variants more often than 
expected (Akawi et al. 2015). This statistical assessment of the likelihood of 
the observed genotypes was complemented with evaluation of the likelihood 
of the phenotypic similarity between cases with variants in the same gene.  
The extreme rarity of some genetic disorders may make it practically 
impossible to find definite statistical support to back up newly identified 
suggestive genotype-phenotype correlations, as noted by MacArthur and 
others. While identification of independent families with variants in the same 
gene is the general requirement for establishment of a new disease gene, it is 
valuable for other researchers to share genetic, clinical and functional data in 
publications even if the initial evidence is only from single families. When 
reporting suggestive gene associations, all supporting data must be reported 
as comprehensively as possible while being open and realistic about the 
extent of confidence in causality. (MacArthur et al. 2014) 
Taken together, NGS technologies coupled with recent analytical 
developments have allowed more efficient gene discovery. As opposed to 
traditional methods, it is now possible to identify new disease genes even in 
the most challenging scenarios, such as in sporadic cases and sample 
collections with substantial genetic and clinical heterogeneity. Highlighting 
the increasing pace of gene discovery during the recent years, 30% of solved 
cases in a study conducted during 2012-2014 had variants in genes 
discovered in year 2011 or later (Yang et al. 2014). It has been estimated that 
most of the remaining ~3000 unsolved Mendelian diseases are likely to be 
solved by the year 2020, if not even earlier (Boycott et al. 2013). 
2.4 Epilepsies 
2.4.1 Definition and classification 
Epilepsies are diseases that involve epileptic seizures, which can be defined 
as “a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain” (Fisher et al. 2005). 
According to the latest clinical definition suggested by the International 
League Against Epilepsy (ILAE), epilepsy is a disease defined by any of the 
following conditions (Fisher et al. 2014): 
 
“1.  At least two unprovoked (or reflex) seizures occurring >24 h apart 
 2. One unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) 
after two unprovoked seizures, occurring over the next 10 years 
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 3.  Diagnosis of an epilepsy syndrome” 
 
Epilepsy is then considered as a disease where patients have an underlying 
pathological predisposition to develop recurrent epileptic seizures. Having a 
seizure associated with a temporary reduction in the threshold to have 
seizures does not lead to a diagnosis of epilepsy (Fisher et al. 2014). Factors 
having the ability to lower the threshold and trigger seizures include for 
example concussion and fever. 
Approximately 4% of individuals will develop epilepsy during their 
lifetime, making epilepsies one of the most common neurological conditions 
(Hesdorffer et al. 2011). Given the relatively high prevalence and adverse 
effects on quality of life, epilepsies represent a substantial health and 
economic burden to the patients and the society (Cardarelli and Smith 2010). 
In addition to adverse health effects of seizures, individuals with epilepsy 
suffer from stigmatisation in the society (de Boer et al. 2008). When 
considering the global burden of epilepsies, it is also to be noted that the vast 
majority of individuals with epilepsy are living in developing countries, 
where access to specialised care and antiepileptic medication are greatly 
limited (de Boer et al. 2008). 
Epilepsies are not a single clinical entity but should rather be considered 
as a group of conditions with seizures being the unifying symptom. 
Epilepsies can be classified based on a number of criteria including the age of 
onset, seizure type, origin of the seizure and aetiology (Berg et al. 2010). 
Seizures fall into two main categories: generalised and focal (Berg et al. 
2010). The former include seizures that involve abnormal brain activity on 
both brain hemispheres. Generalised seizures can be divided into six further 
categories: tonic-clonic, absence, myoclonic, clonic, tonic and atonic. Tonic-
clonic seizures, for example, initiate with the tonic phase, which is brief and 
where consciousness is lost, body stiffens and one falls down. The following 
clonic phase lasts longer and involves primarily rhythmic muscle 
contractions. In focal seizures, epileptic brain activity is localised to one brain 
hemisphere and the related symptoms depend on the origin of seizure, given 
that various brain regions have different functions. One may for example stay 
conscious during a focal seizure but not always. 
According to ILAE, three are three distinctive aetiological classes of 
epilepsies: genetic, structural/metabolic and unknown (Berg et al. 2010). In 
genetic epilepsies seizures are considered to be caused directly by known or 
presumed genetic lesions, however, the definition does not rule out the role 
of environmental factors. This category was formerly called idiopathic, 
indicating that the underlying cause of the disease is unknown. It is 
estimated that genetic factors underlie 70% of all epilepsy cases (Hildebrand 
et al. 2013). Genetic generalised epilepsies (GGE) constitute the most 
common form of genetic epilepsies accounting for approximately 30% of all 
cases (Panayiotopoulos 2005). GGEs emerge typically in the childhood or 
adolescence and they are generally not associated with cognitive dysfunction 
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or developmental delay. Seizures are generally well controlled with 
appropriate antiepileptic drugs in GGEs (Panayiotopoulos 2005). Epileptic 
encephalopathies (EE) are another subgroup of genetic epilepsies. They are 
individually rare but collectively account for an important fraction of 
epilepsies. EEs are early-onset and severe forms of epilepsies where epileptic 
brain activity contribute to cognitive and behavioural defects (Berg et al. 
2010). They do not respond well to antiepileptic drugs and are associated 
with developmental delay or regression and poor prognosis (Khan and Al 
Baradie 2012).  
Genetic epilepsies can be further divided into epilepsy syndromes with 
distinctive electroclinical features and these can be arranged based on their 
onset (neonatal, infancy, childhood, adolescence-adult) and characteristics 
findings in electroencephalogram (EEG) (Berg et al. 2010). EEG is an 
important diagnostic tool in epilepsies and it records the combined electrical 
activity of the brain with brainwave patterns (Noachtar and Rémi 2009). 
These patterns are abnormal in epileptic brain and many epilepsy syndromes 
have a typical EEG pattern. Magnetic resonance imaging (MRI) is another 
commonly used method in epilepsy diagnostics, since it can reveal structural 
defects in the brain that underlie the seizures.  
The second aetiological category includes epilepsies that are caused by 
structural lesions or metabolic conditions (Berg et al. 2010). Structural 
defects, which increase the risk of epileptic activity, may arise due to 
acquired disorders such as trauma, stroke and infection. Notably, this 
category can also include genetic disorders, when the underlying genetic 
variants result in structural lesions or other defects causing seizures. 
Tuberous sclerosis is one example of such disorders. 
It is important to note that symptoms are not limited to seizures in many 
epileptic syndromes. The effect of the underlying causal factors is not often 
restricted exclusively on mechanisms regulating seizure activity but also 
other aspects of development and function of the central nervous system 
(CNS) and other tissues can be affected. Therefore, individuals with epilepsy 
may have other neurological symptoms, dysmorphic features, muscular 
disorders or other defects in any tissue. Seizures are also a common 
comorbidity of various other neurological and neurodevelopmental disorders 
where epilepsy is not the primary phenotype. These include, for instance, 
autism spectrum disorders, migraine and intellectual disability, as well as 
many other genetic syndromes (Ottman and Lipton 1994; Myers and Mefford 
2015).  
2.4.2 Genetics of epilepsies 
As mentioned in the previous section and illustrated in Figure 6, genetic 
factors underlie majority of epilepsies. Even though epilepsies have been 
considered a sacred or magical disease throughout the human history, 
already Hippocratic texts two and half millennia ago postulated the 
importance of the inherited component in epilepsies (Riggs and Riggs 2005). 
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The role of genetic factors in epilepsies has been formally demonstrated in 
family-based studies showing that relatives of affected individuals are in 
higher risk to have epilepsy and in twin studies showing that monozygotic 
twins have higher concordance of epilepsy compared to dizygotic twins 
(Annegers et al. 1982; Berkovic et al. 1998).  
 
Figure 6 Contribution of genetic factors to epilepsy. The figure illustrates the 
contribution of genetic and acquired/environmental factors in the aetiology of epilepsies. 
Genetic factors underlie the majority of epilepsies, the most common forms being polygenic 
and rare forms monogenic. In addition, acquired forms of epilepsies with little genetic 
contribution underlie a substantial proportion of epilepsies. Adapted from Hildebrand et al. 
(2013). 
First gene discoveries in epilepsies were done in the 1990s. In 1990, the 
genetic defect underlying myoclonic epilepsy and ragged-red fiber disease, a 
syndromic form of epilepsy involving myopathy and spasticity in addition to 
myoclonic seizures, was identified in the mitochondrial genome (Shoffner et 
al. 1990). In epilepsy syndromes where seizures are clearly the predominant 
clinical feature, the first causal variant was identified in CHRNA4, encoding a 
nicotinic acetylcholine receptor subunit (Steinlein et al. 1995). This variant 
causes autosomal dominant nocturnal frontal lobe epilepsy. One of the most 
important gene discoveries occurring in the turn of the millennium was
identification of pathogenic variants in KCNQ2 and SCN1A, the former 
encoding a neuronal potassium channel and the latter a neuronal sodium 
channel (Singh et al. 1998; Escayg et al. 2000). Variants in these genes, 
either inherited or de novo, have turned out to be common causes of less-
severe forms of familial epilepsies with no effect on cognition or development 
but also of severe forms of EEs (Claes et al. 2001; Weckhuysen et al. 2012). 
Despite these individual success stories in epilepsy genetics, in general, as 
with other genetic disorders, pace of epilepsy gene discovery was relatively 
slow until the NGS era.
2.4.2.1 Genetics of common and focal epilepsies 
The genetic background of most common forms of epilepsies, GGEs, is 
considered to be primarily oligo- or polygenic with multiple genetic factors 
and environmental factors contributing to the disease onset (Marini et al. 
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2004; Myers and Mefford 2015). It is therefore not surprising that genes 
which would individually explain a large proportion of cases have not been 
identified and that the vast majority of GGE cases remain genetically 
unexplained. In families where single-gene forms of GGEs have been 
identified, it is typical that the underlying variants are not fully penetrant and 
show intra-familial clinical variability ranging from no clinical diagnosis of 
epilepsy to different manifestations of epilepsies (Meisler MH 2012). This 
highlights the role of genetic modifiers and other factors in these diseases.  
Importantly, over the past few years, CNVs have been implicated in GGEs. 
For example, recurrent microdeletions in chromosomes 15q11.2, 15q13.3 and 
16p13.11 are enriched in individuals with GGE (i.e., they are not fully 
penetrant), and each variant is found in <1% of all cases (Helbig et al. 2009; 
de Kovel et al. 2010). Additionally, microdeletions in other loci overlapping 
with neurodevelopmentally important genes are enriched in GGE cases (Lal 
et al. 2015). Therefore, collectively CNVs seem to account for a substantial 
proportion of the genetic component of GGEs. In common epilepsies, 
genome-wide association studies (GWAS), a commonly used approach in 
complex disease genetic to identify disease loci (Stranger et al. 2011), have 
had little success due to small sample sizes of the studies with limited 
statistical power to detect association. In the largest meta-analysis of GGE 
GWASs, only two loci were identified, one being SCN1A (ILAE Consortium 
on Complex Epilepsies 2014). The same gene was also one of the few 
significant loci identified in a GWAS of febrile seizures, further 
demonstrating the role of SCN1A as probably the single most important 
epilepsy gene underlying a variety of epilepsies (Feenstra et al. 2014).  
While most cases of focal epilepsies remain unsolved, a few genes have 
been identified. The most important of them is DEPDC5, a member of the 
mTOR pathway (Dibbens et al. 2013; Ishida et al. 2013). Interestingly, the 
role of somatic mutations have been demonstrated in focal epilepsies (Baulac 
et al. 2015; Lim et al. 2015). It remains to be seen what the contribution of 
somatic mutations is in other epilepsies. 
2.4.2.2 Genetics of rare and severe epilepsy syndromes 
Empowered by NGS technologies, WES in particular, gene discovery in 
infantile- or childhood-onset severe epilepsy syndromes including EEs has 
accelerated during the past years with tens of new genes identified (reviewed 
by Myers and Mefford 2015). The success reflects the fact that most of them 
are Mendelian and caused by variants of large effect (Figure 6), and thus 
NGS provides a powerful platform to dissect their genetic basis. Compared to 
other genetic disorders, diagnostic yield of WES in severe epilepsies appear 
to be higher based on a recent study: 38% vs. 28% (Helbig et al. 2016). This 
suggests that interpretation of disease-causing variation is more 
straightforward in severe epilepsies. Possible causes could be that the genes 
mutated in severe neurological disorders have less background variation 
compared to, for example, those in immunological disorders (Petrovski et al. 
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2013) or that the genetic basis of epilepsy syndromes is generally more 
simple. Another important factor explaining the success in genetics research 
of rare epilepsies is that the epilepsy community has joined forces to form 
large sequencing consortia, which greatly increases power to make new gene 
discoveries (e.g., Epi4K Consortium and Epilepsy Phenome/Genome Project 
2013; EuroEPINOMICS-RES Consortium et al. 2014). In addition to 
epilepsy-specific studies, individuals with epileptic syndromes are often 
included in other large-scale sequencing efforts (Yang et al. 2014; The 
Deciphering Developmental Disorders Study 2015). 
The role of de novo mutations in epilepsies was first demonstrated with 
identification of SCN1A as the major gene underlying severe myoclonic 
epilepsy of infancy (also known as Dravet syndrome) (Claes et al. 2001). 
Gene discoveries in the NGS era have confirmed that majority of the 
pathogenic variants underlying severe Mendelian forms of epilepsies occur 
de novo, which also explains why many of them remained unsolved using 
traditional methods. 
Pathogenic variants associated with most of the recent gene discoveries 
are point mutations or small-scale indels, with gain-of-function, loss-of-
function or dominant-negative effect on protein function (see also section 
2.4.3 for the molecular mechanisms of epilepsies). It is also to be noted, 
however, that in severe forms of epilepsies large CNVs may explain 7-12% of 
all cases, highlighting the importance of CNV analysis in the diagnostics 
(Mefford et al. 2011; Sisodiya 2015). Identification of CNVs have in some 
cases facilitated characterization of new epilepsy genes, such as STXBP1 
(Saitsu et al. 2008). 
Taken together, epilepsies are associated with remarkable genetic 
heterogeneity, both of locus and allelic type. First, this is illustrated by the 
large number of genes linked to epilepsies. Based on current knowledge, 
there are at least 73 genes where variants can cause a disorder classified 
primarily under epilepsies (EpiPM Consortium 2015). If disorders where 
seizures are a comorbid feature are also included, there are ~500 such genes 
(Ran et al. 2015b). Secondly, it has become evident that diseases with similar 
clinical features can be caused by variants in different genes (e.g., Suls et al. 
2013) and also that variants within a single gene can result in substantially 
different epilepsy phenotypes or other related neurological conditions 
(Noebels 2015). In other words, clinical classifications of epilepsies have little 
overlap with the genetic aetiology of epilepsies. Based on these observations, 
utility of gene panels in diagnostics of epilepsies can be questioned, since it is 
often difficult to select a correct set of genes to be tested and because the 
number of new epilepsy genes grows so rapidly.  
2.4.3 Pathomechanisms of epilepsies 
One of the basic mechanisms of the nervous system function is that the 
billions of neurons, which form complex networks, communicate with each 
other via synaptic connections. This process is called synaptic transmission, 
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which can be either excitatory or inhibitory. Synapses can be chemical or 
electrical, of which chemical synapses are most prevalent. (Purves et al. 2011) 
Dendrites are a branched structure of a neuron, where synapses are 
located (Figure 7). Thousands of synapses, either excitatory or inhibitory, 
can be present in each dendrite and they can originate from multiple 
presynaptic neurons. Dendrites are responsible for processing of these 
synaptic inputs. Postsynaptic potentials are changes in the membrane 
potential at the synaptic terminal of the neuron that receives the signal. 
Postsynaptic potential generated by each active synapse is small. These 
excitatory and inhibitory postsynaptic potentials are, however, added 
together and if the sum exceeds a threshold, action potential is triggered. 
Action potential is the electric signal that travels along the axon and sends 
information to other neurons. In a simplistic example, if the effect of five 
excitatory postsynaptic potentials is counteracted by five inhibitory 
potentials, no action potential is fired. In chemical synapses, the 
neurotransmitter that is released from the presynapse to the postsynapse via 
the synaptic cleft determines the nature of the synaptic potential. Gamma-
aminobutyric acid (GABA) is the most common inhibitory neurotransmitter, 
while glutamate is an example of a neurotransmitter in excitatory synapses. 
(Purves et al. 2011) 
 
Figure 7 A neuron. (The image released into the public domain was reused from 
https://en.wikipedia.org/wiki/File:Complete_neuron_cell_diagram_en.svg) 
A unified pathomechanism for epileptic seizures can be described as the 
imbalance of inhibition and excitation in the nervous system (Scharfman 
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2007; Staley 2015). This can result from having too little inhibition 
(disinhibition) or too much excitation. Thus, seizure activity may arise when 
the mechanisms inhibiting neuronal firing are impaired or the system 
facilitating excitation is promoted.  
The hundreds of genes known to be linked to epilepsies encode proteins 
with a large variety functions and many of them do not have any obvious 
association with potential mechanisms controlling the balance of inhibition 
and excitation. Initially, however, when first genes associated with epilepsies 
had been identified, the functional connection of the epilepsy genes and the 
imbalance between excitation and disinhibition was more evident (George 
2004). Many of these genes encode neuronal ion channels, which have an 
important role in regulation of neuronal excitability. For example, some of 
these proteins included voltage-gated potassium or sodium channels genes, 
whose function is to generate and propagate action potentials. Depending on 
the type of neurons in which the ion channels are expressed and type of the 
mutation (gain-of-function, loss-of-function), dysfunction of these epilepsy 
associated ion channel causes either too much excitation or too little 
inhibition. For example, if a missense variant disrupts sodium channel 
function in an inhibitory neuron, it leads to decreased inhibition and 
hyperexcitability of a neuronal network.  
Given the strong link of ion channel genes and epilepsies, epilepsies have 
been considered as ‘channelopathies’, i.e., diseases where ion channel 
function is impaired. While many of the newly identified epilepsy genes 
support the important role of ion channels, the functional spectrum of 
epilepsy associated genes has expanded dramatically in the NGS era (Figure 
8). Synaptic transmission, transcriptional regulation, chromatin remodelling 
and cell growth regulation are examples of pathways that are now linked to 
severe forms of epilepsies (Myers and Mefford 2015; McTague et al. 2016). 
These proteins can be located anywhere in the neurons, from dendrites to the 
synapses, and function from early development to further maturation of 
neurotransmission. Specifically, many of the proteins linked to epilepsies 
appear to be over-represented in processes controlling neuronal inhibition 
(Noebels 2015).  
Unravelling the genetic basis and molecular pathobiology of epilepsies 
may provide new targets for antiepileptic treatments. Already now knowing 
the specific genetic and molecular defect in a patient with epilepsy may guide 
selecting appropriate treatment options. This works in both ways, a more 
effective antiepileptic drug that is known to work well with the specific 
genetic epilepsy syndrome may be selected, and, on the other hand, drugs 
with known adverse effects may be avoided (Loscher et al. 2013). 
Importantly, recently published studies have provided first evidence that 
characterisation of the genetic basis of a disease may lead to effective 
targeted therapies. For instance, inherited or de novo variants in KCNT1, 
encoding a voltage-gated potassium channel, cause at least two forms of 
epilepsies with varying severity (Barcia et al. 2012; Heron et al. 2012). Some 
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of the KCNT1 patients have gain-of-function mutations that cause the ion 
channel to be too active. Interestingly, functional studies showed that 
quinidine, which is a known antiarrhythmic molecule, is able to partially 
reverse the effect of the mutation (Milligan et al. 2014). Promisingly, 
administration of quinidine lead to significant reduction in seizure frequency 
in two of three patients with KCNT1 positive epilepsy (Bearden et al. 2014; 
Mikati et al. 2015). Other Mendelian epilepsies where genetic diagnosis may 
assist selection of antiepileptic treatment are those associated with 
pathogenic variants in GRIN2A, KCNQ2, SCN1A and DEPDC5 (Baraban et 
al. 2013; Krueger et al. 2013; Orhan et al. 2014; Pierson et al. 2014; Myers 




Figure 8 Molecular mechanisms underlying paediatric epileptic encephalopathies. 
The figure illustrates the wide spectrum of functional roles that proteins defective in epileptic 
encephalopathies have in the development and function of the central nervous system 
neurons. Reprinted from The Lancet Neurology, McTague et al. (2016), “The genetic 
landscape of the epileptic encephalopathies of infancy and childhood”, © 2016, with 
permission from Elsevier. 
2.4.4 Progressive myoclonus epilepsies 
Progressive myoclonus epilepsies (PME), the main focus of this thesis 
together with severe infantile-onset epileptic syndromes, are a group of rare, 
genetic and severe epilepsies (reviewed by Berkovic et al. 1986; Shahwan et 
al. 2005; Kälviäinen 2015). PMEs are phenotypically heterogeneous but they 
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are characterised by three main features: myoclonic seizures (brief jerks of a 
muscle or a muscle group, also called myoclonus, which, notably, is not 
always a sign of epileptiform activity), tonic-clonic seizures and progressive 
deterioration of symptoms over time due to neurodegeneration. The disease 
onset is usually in early to late-childhood or adolescence. In rare cases, PME 
may also present in adulthood.  
In PMEs, myoclonus is typically disabling and affects daily activities. It 
may occur without stimuli or be triggered by, for example, noise or light. In 
addition to seizures, PMEs can be associated with other neurological 
features, such as ataxia (impaired coordination of movements), dysarthria 
(motor speech disorder) and dementia. Due to disabling myoclonus and 
ataxia, wheelchair is often needed. In the most common form of PME, 
Unverricht-Lundborg disease (ULD), cognition is only mildly, if at all, 
affected and the disease does not affect lifespan. On the contrary, Lafora 
disease and neuronal ceroid lipofuscinoses (NCL) are examples of PMEs that 
present with more rapid progression and early death. There is no cure 
available to any of the PME subtypes and care is symptomatic. Seizures, in 
particular myoclonus, are generally refractory to medication. 
Diagnosis of PMEs in the early course of the disease in particular is 
challenging due to nonspecific symptoms and clinical overlap with other 
epilepsies and neurological disorders (Knupp and Wirrell 2014). In some 
forms of PMEs (Lafora disease, NCLs), inclusion bodies seen in skin biopsies 
can be used in the diagnostics, but generally, there are not any distinguishing 
biomarkers. Ultimately, genetic diagnosis is needed for specific diagnosis, 
and while there are many molecularly defined PME subtypes (Table 3), 
many PME cases are still molecularly unsolved (Figure 9) (Franceschetti et 
al. 2014). 
The majority of molecularly characterised PMEs are autosomal 
recessively inherited (Table 3). The most extensive study aiming to 
characterise the genetic aetiology of PMEs was conducted in a nationwide 
collection of 204 patients in Italy (Franceschetti et al. 2014). However, this 
study screened only known PME genes, and no large-scale efforts dissecting 
the genetic basis of PMEs using NGS technologies have been conducted prior 
to this study. Based on the study by Franceschetti and colleagues, ULD (38% 
of the cohort), Lafora disease (16%) and NCLs (6%) are the most common 
forms of PMEs (Figure 9). However, since these PME subtypes are 
autosomal recessively inherited, with population specific allele frequencies 
affecting the disease prevalence, same findings may not apply to all 
populations. In fact, Western Mediterranean countries together with Finland 
(1 in 20,000 births) have the highest incidence of ULD worldwide (Shahwan 
et al. 2005). 
PME-associated genes encode a functionally diverse set of proteins 
(Table 3), but the pathomechanisms have remained largely uncharacterised. 
Many of the PMEs are molecularly linked to endosomal or lysosomal 
dysfunction, which leads to neurodegeneration and seizures. For example, 
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NCLs are caused by accumulation of lipopigments in lysosomes (Kollmann et 
al. 2013). 
Table 3. Genetics of PME subtypes. 
PME subtype Inheritance 
pattern 
Gene(s) Protein function/molecular 
pathway 




AR EPM2A, NHLRC1 Glycogen metabolism 
NCLs AR/AD PPT1, TPP1, CLN3, CLN5, 
CLN6, MFSD8, CLN8, 
CTSD, DNAJC5, CTSF, 
ATP13A2, GRN 
Many lysosomal enzymes or 
membrane proteins 
EPM3 AR KCTD7 Interaction with potassium ion 
channels? 
AMRF (EPM4) AR SCARB2 Lysosomal membrane protein 
North sea PME 
(EPM6) 
AR GOSR2 Golgi vesicle transport 
MERRF Mitochondrial MT-TK, MT-TF, MT-TL1, 
MT-TI, MT-TP 
Mitochondrial transfer-RNAs 
Sialidoses AR NEU1 Lysosomal enzyme which 
breaks down oligosaccharides 
DRPLA AD ATN1 Accumulation of ATN1 in 
neurons due to repeat 
expansion 
MEAK1 (EPM7) AD/de novo KCNC1 Neuronal voltage-gated 
potassium ion channel 
PME/EPM, progressive myoclonus epilepsy; ULD, Unverricht-Lundborg disease; AR, 
autosomal recessive; NCLs, neuronal ceroid lipofuscinoses; AD, autosomal dominant; 
AMRF, action myoclonus with renal failure; MERRF, myoclonus epilepsy and ragged-red 
fibers; DRPLA, dentatorubro-pallidoluysian atrophy; MEAK, myoclonus epilepsy and ataxia 
due to potassium channel mutation. 




Figure 9 Genetic causes of PME in a nationwide cohort. Data in the figure is from a 
multicenter study where 204 patients were collected in a 15-year period in Italy 
(Franceschetti et al. 2014). Genes in blue are autosomal recessively inherited and red color 
indicates myoclonus epilepsy and ragged-red fibers caused by mitochondrial DNA variants. 
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3 AIMS OF THE STUDY 
The aim of this thesis was to decipher the molecular genetic basis of PMEs 
and severe, infantile-onset epileptic syndromes.  
Given the variability in clinical presentations in the studied cohorts, we 
hypothesised that they are genetically heterogeneous. Moreover, as the study 
subjects had been screened negative for pathogenic changes in a varying 
number of known disease genes, we hypothesised that the cohort may be 
enriched for novel underlying genetic causes. With these considerations in 
mind, we hypothesised that WES would provide a powerful and hypothesis-
free approach to establish new genotype-phenotype associations in these 
syndromes. 
  
Specifically the aims were: 
  
1. To identify disease-causing genetic variants in individuals with 
unexplained PME or severe, infantile-onset epileptic syndrome by 
WES. 
 
2. To identify novel genes underlying these syndromes and to confirm 
pathogenicity of the identified variants by functional assays. 
 
3. To improve diagnostics of the syndromes and to provide new insight 




4 MATERIALS AND METHODS 
4.1 Study subjects 
4.1.1 Progressive myoclonus epilepsy patients (I)  
The WES cohort consisting of 84 unrelated individuals with PME was 
collected through international collaboration in over a 25-year period. The 
collection of subjects and their clinical information was coordinated by 
Professors Samuel F. Berkovic (University of Melbourne, Australia) and 
Anna-Elina Lehesjoki (University of Helsinki, Finland). Approximately half 
of the patients showed a clinical presentation similar to ULD, i.e. onset at late 
childhood or adolescence and cognition not deteriorated. Majority of the 
cases (73) were of European descent and approximately half Italian. The 
remaining cases were of Western Asian (7), Southern Asian (3) or Chinese (1) 
origin. All individuals were excluded for variants in CSTB, the most common 
PME gene. The extent of other genetic studies varied among the study cohort. 
Parents and family members were not subjected to WES but were recruited 
for segregation analysis of identified candidate variants. 
Seventy probands had no previous family history of PME. Three cases had 
either an affected parent or offspring. Family pedigrees of eleven cases were 
suggestive of an autosomal recessive inheritance of the disease. Fifteen 
patients were reported to be born to consanguineous parents. Analysis of 
exome variant data for inbreeding by FEstim (Leutenegger et al. 2003) 
implemented in FSuite v. 1.0.2 (Gazal et al. 2014) indicated that eighteen 
patients were from consanguineous families. Cryptic relatedness between 
study subjects was not detected by PLINK identical-by-descent analysis 
(Purcell et al. 2007). 
Additionally, a secondary cohort of 28 individuals with PME or possible 
PME was collected for Sanger sequencing screening of candidate variants 
identified in the primary cohort. 
4.1.2 Finnish patients with severe, infantile-onset epileptic syndromes 
(II,III)  
Children showing severe, infantile-onset epileptic syndromes with suspected 
genetic aetiology were collected in over 20-year period via Finnish university 
hospitals with the aim to identify the underlying genetic cause. Eventually, 
30 children without a genetic diagnosis were subjected to WES. A manuscript 
of the analysis of the whole WES cohort is under preparation (A. Laari, M. 
Muona et al.), while identification of novel disease genes in families in the 
WES cohort is described in studies II and III included in this thesis.  
Patients in the study cohort have severe neurodevelopmental conditions 
with epilepsy. A subset of these syndromes may be considered as EEs where 
seizure activity itself contributes to cognitive and behavioural dysfunction 
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and disease progression. In the remaining cases, neurodevelopmental defects 
precede the onset of seizure activity, i.e., genetic defects are not directly 
linked to seizure development. All cases had been screened negative for the 
Finnish founder mutation in the gene underlying the PEHO syndrome, which 
is an early-onset encephalopathy with epilepsy belonging to the Finnish 
disease heritage (A.-K. Anttonen et al. under review). Majority of patients 
were screened for large CNVs either prior to this study or as part of this study 
(see section 4.2.10).  
In study II, a nonconsanguineous family with two affected siblings was 
ascertained within the above described sample collection (denoted as “family 
A”). The patients have an infantile-onset encephalopathy which initially 
presented with irritability followed by dystonic movements, epilepsy, 
intellectual disability and stagnation of development. WES was performed 
for the parents and the index case (II, Figure 1B). In study III, a proband 
with a rapidly progressing encephalopathy with epilepsy was ascertained 
within the same study cohort and subjected to WES. The healthy parents 
were not known to be closely related. The proband has two unaffected 
siblings and no family history of epilepsy (III, Figure 2A).  
Additionally in study II, a nonconsanguineous family with four affected 
siblings manifesting with a similar disease to patients in family A in study II 
was ascertained independently from the above described sample collection 
(denoted as “family B”). Two affected siblings, one unaffected sibling and 
parents were subjected to WES (II, Figure 1B). A detailed description of the 
patients’ symptoms in families A and B is presented in the original 
publication II. 
4.1.3 Ethical issues (I-III) 
Informed consent for DNA analysis was obtained from patients or legal 
guardians of the patients in line with local institutional review board 
requirements at time of collection. The genetic studies were approved by the 
ethical board of Helsinki University Hospital (I-III; decision no. 
424/E7/2002, amended in 2011, and 183/13/03/03/2009). 
4.2 Production and analysis of genetic data 
4.2.1 Whole-exome sequencing (I-III) 
WES was carried out at the Wellcome Trust Sanger Institute (WTSI; 
Hinxton, Cambridge, UK) in all studies with the exception of members of 
family B in study II that were exome-sequenced at the sequencing core 
facility of the Institute for Molecular Medicine Finland (FIMM; Helsinki, 
Finland).  
Briefly, genomic DNA extracted from peripheral blood of subjects was 
fragmented and subjected to library creation using standard Illumina (San 
Diego, CA, USA) paired-end protocols. For samples sequenced at WTSI, 
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exome targets were captured with SureSelect Human All Exon 50 Mb V3 
RNA baits (Agilent Technologies, Santa Clara, CA, USA). For samples 
processed at FIMM, Nimblegen SeqCap EZ Human Exome Library v2.0 was 
used. Paired-end sequencing (reads 75 bp at WTSI, 93 bp at FIMM) was 
performed using Illumina HiSeq 2000 (WTSI) or HiSeq 1500 (FIMM). 
4.2.2 Sequence read processing (I-III) 
Sequence reads produced at WTSI were aligned to the human reference 
genome using the Burrows-Wheeler Alignment Tool v. 0.5.10-mt (Li and 
Durbin 2009). The 1000 Genomes Phase II reference (hs37d5) was used as 
the reference genome. It is based on GRCh37 and consists of chromosomes 
1–22, X, Y, as well as the mitochondrial genome (rCRS mitochondrial 
sequence NC_012920). Duplicate reads were marked using the Picard toolkit 
v. 1.107 (http://broadinstitute.github.io/picard/). Sequence reads were 
further processed by performing local realignment around known indel 
locations and recalibrating base quality scores were recalibrated with GATK 
tool package v. 2.8.1 (McKenna et al. 2010; DePristo et al. 2011; Van der 
Auwera et al. 2013).  
Sequence reads produced at FIMM were processed by the bioinformatics 
core facility of the institute. Briefly, reads were processed and aligned to the 
human reference genome hg19 (GRCh37) with a protocol described by 
Sulonen and colleagues with minor modifications (Sulonen et al. 2011). 
4.2.3 Single-nucleotide and indel variant calling (I-III) 
As a primary approach, sequence variants were called ‘jointly’ so that all 
exomes of a dataset were analysed simultaneously. The exomes as part of the 
joint calling process were sequenced at WTSI, i.e., exomes of individuals 
from family B in study II were called separately because they were sequenced 
at FIMM. In the joint approach, SNVs and indels were called using 
HaplotypeCaller algorithm of GATK (v. 2.8.1 in study I, v. 3.3 in studies II 
and III). In study I, variants for the 84 PME exomes were called jointly. In 
studies II and III, the variant calling dataset consisted of the 84 PME exomes 
accompanied with 43 exomes from the infantile-onset epileptic syndrome 
cohort described in section 4.1.2. The 43 exomes from the infantile onset 
epileptic syndrome cohort includes thirty patient exomes, ten parental 
exomes and three exomes from other samples. Recalibration of variant 
quality scores and quality-based filtering of called variants was done with 
GATK VariantRecalibrator as per GATK Best Practices protocol with minor 
modifications. In study I, a sensitivity cut-off of 99.0% was used for both 
SNVs and indels. In studies II and III, this cut-off was 99.75%. In addition, 
individual variant calls with less than five reads at the site were filtered out. 
We also utilised single-sample variant calling methods (GATK, samtools) to 
compare the performance of different approaches and to confirm that any 
variants in known disease genes or potential new genetic causes were not 
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missed using the joint approach. For the comparison variant call sets 
obtained with single-sample calling methods, quality-based assessment of 
variants was done using ‘hard filters’ on various quality annotation scores. 
For exomes generated at FIMM (study II, family B), SNVs and indels were 
called using samtools (Li et al. 2009) as described previously (Sulonen et al. 
2011). 
4.2.4 Analysis of mitochondrial DNA variants (I,III) 
Variants in mitochondrial DNA (mtDNA) underlie one form of PME 
(Myoclonic epilepsy with ragged-red fibers) (Shoffner et al. 1990) and early-
onset syndromes with seizures (Mitochondrial encephalopathy with lactic 
acidosis and stroke-like episodes and Neuropathy, ataxia, and retinitis 
pigmentosa) (Goto et al. 1990; Holt et al. 1990). Hence, sequence data were 
analysed for pathogenic changes in mtDNA in studies I and III where 
mitochondrial inheritance was a possibility. Exome capture kits used in this 
study did not contain baits for mtDNA, but due to abundance of mtDNA in 
cells, enough mtDNA sequence reads were produced to allow detection of 
variants with a moderate heteroplasmy level (average read depth of 32.7 in 
study I and 35.7 in study III). Variants were called using GATK 
UnifiedGenotyper (study I) or samtools (study III; Li et al. (2009)). Known 
mtDNA polymorphisms and pathogenic variants were annotated based on 
the MITOMAP database (http://www.mitomap.org). 
4.2.5 Variant and gene annotation (I-III) 
Variant consequences were annotated using Variant Effect Predictor (release 
75 in study I, release 78 in studies II and III; McLaren et al. (2010)). In silico 
prediction of deleteriousness of missense variants was done using CADD 
(Kircher et al. 2014), PolyPhen HumVar (Adzhubei et al. 2010), SIFT (Kumar 
et al. 2009) and MutationTaster (Schwarz et al. 2010; Schwarz et al. 2014).  
Variant frequencies in the general population were assessed based on the 
following databases: 1000 genomes project (study I: 1092 samples of the 
phase 1 release; studies II and III: 2535 samples of the phase 3 release), EVS 
of the NHLBI GO Exome Sequencing Project (studies I-III: 6503 samples of 
the 0.0.25 release), Finnish exomes of the Sequencing Initiative Suomi 
(SISu) project (study I: 3268 samples) and ExAC (studies II and III: 60,706 
samples of the v. 0.3 release). Notably, ExAC v. 0.3 release contains over 
3,200 exomes of the SISu project as well as samples from the 1000 genomes 
and EVS projects. 
Association of individual variants to human disease was annotated based 
on NCBI ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/), gene-
specific online variant databases and literature search. Association of genes 
to human disease was annotated based on the Online Mendelian Inheritance 
in Man, OMIM® database (Hamosh et al. 2005), neurological disease gene 
panels (Lemke et al. 2012) and literature search. 
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4.2.6 Variant filtering and analysis (I-III)
Variant data were initially analysed for changes in previously established 
disease genes. For individuals who were without likely pathogenic variants in 
known disease genes, variants in novel disease genes were explored.  
We applied variant filtering strategies based on the possible underlying 
inheritance patterns (Figure 10). As described in section 4.1, the majority 
(70) of individuals with PME in study I are sporadic so the exome data was 
analysed for recessive (autosomal and X-linked), de novo (an indirect 
approach was used since parents were not exome-sequenced, see also below) 
and mtDNA variants (I, Figure 1a). In 11 ‘recessive’ families (probands have 
affected siblings or cousins) and three ‘dominant’ families (affected parent-
offspring pair), recessive or dominant filtering strategy was primarily 
applied, respectively. In study II, where the suggestive pattern of inheritance 
was autosomal recessive in both families A and B, autosomal recessive 
variants were primarily searched while considering the possibility of 
germline mosaicism of heterozygous variants in either parent (II, Table S2). 
In study III, where the exome of a sporadic female patient was analysed, 
autosomal recessive, de novo (indirect approach) and mtDNA were analysed 
(III, supplemental figure e-1). 
 
Figure 10 Pedigree structures and primary variant filtering strategies of studies I-III. 
Dashed lines indicate individuals who where whole-exome sequenced. Illustrations of 
pedigrees of studies II and III are actual representations of the studied families, whereas the 
pedigree pictures of study I are simplified and only indicate the various types of family 
structures that are present in the study. 
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Variants within gene transcripts of the CCDS database, implemented in 
Ensembl release 75 (study I) or 78 (studies II and III), were primarily 
considered but less conservative Ensembl gene transcripts were also used in 
parallel. Variants with the following consequences were included: missense 
variant, initiator codon variant, splice donor or acceptor variant, stop lost, 
stop gained, inframe insertion or deletion, and frameshift variant. Inframe 
indels in tandem repeat regions (Benson 1999) obtained from UCSC Genome 
Browser (Kent et al. 2002) were excluded. 
In recessive filtering, homozygous, hemizygous (when X-linked variants 
were analysed) and potentially compound heterozygous variants were 
included. Variants with <1% allele frequency and those not present as 
homozygous or hemizygous in the databases listed in section 4.2.5 were 
included. Since parents were not exome sequenced (besides in study II), 
phase information of heterozygous variants (including compound 
heterozygous) could not be directly assessed except for those residing in 
same sequence reads. As an indirect approach, we utilised phase information 
of variants from the 1000 genomes and SISu data. Ultimately, the phase of 
candidate compound heterozygous variants was done by analysing the 
segregation with Sanger sequencing (see section 4.2.7). 
In studies I and III, we analysed de novo variants using an indirect 
approach, since parental samples were not exome sequenced. We included 
only heterozygous variants that are not present in the population variant 
databases listed in section 4.2.5 or in NCBI dbSNP database (build 138; 
http://www.ncbi.nlm.nih.gov/snp), except clinically associated variants in 
NCBI ClinVar. In other words, we assumed complete penetrance of the 
variants. This was done because in study I, most patients have disease onset 
before adulthood with maximum onset at 26 years and in study III, patient 
had a severe early-onset disease. In study III, all variants passing the ‘de 
novo’ filtering were subjected to segregation analysis by Sanger sequencing, 
whereas in study I only selected variants were further analysed (see sections 
4.2.8 and 4.2.9). 
Quality of variants passing the filtering was assessed with Integrative 
Genomic Viewer (https://www.broadinstitute.org/igv/; Robinson et al. 
(2011)). Majority of low quality variant calls were already flagged at steps 
described in section 4.2.3, but some false positive variants, many of which 
occur in segmental duplication regions, were removed at this stage. The final 
high-confidence variants were analysed for pathogenic changes (see sections 
4.2.8 and 4.2.9). 
Additional details regarding the variant filtering process are presented in 
original publications of the studies. 
4.2.7 Variant validation and segregation analysis (I-III) 
Candidate variants identified by WES were validated and their segregation 
analysed by bidirectional Sanger sequencing using ABI BigDye 3.1 chemistry 
and ABI 3730xl DNA Analyzer (FIMM sequencing laboratory, Helsinki, 
 
63 
Finland). Primers were designed using Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/; Ye et al. (2012)) and 
sequences analysed with Sequencher (Gene Codes Corporation, Ann Arbor, 
MI, USA).  
4.2.8 Variant pathogenicity classification (I) 
In study I, interpretation of variants was done according to similar 
considerations as recently proposed by ACMG (Richards et al. 2015). 
Clinicians were involved in the interpretation process for each case.  
We classified variants passing the filtering as pathogenic, probably 
pathogenic or unlikely pathogenic. Detailed classification criteria are 
presented in the original publication of study I. Briefly, factors we took into 
consideration were among others compatibility of the patient phenotype to 
those in previously reported cases, previous reports of the pathogenicity of 
the variant, conservation of the altered amino acid and information of the 
functional domains of the protein. To be classified as pathogenic or probably 
pathogenic, segregation pattern of the variant(s) had to concur with that of 
reported for previous cases in the literature. 
4.2.9 Search for novel progessive myoclonus epilepsy genes in the 
exome variant data (I) 
PME exomes, where analysis of known disease genes did not yield probably 
pathogenic or pathogenic variants, were collectively analysed for variants in 
novel disease genes (n=69). We used overlap based strategy (Figure 4, p. 
36), i.e., we looked for genes with variants in multiple PME exomes. After 
filtering variants based on recessive or dominant/de novo approaches, we 
ranked the remaining genes based on the number of cases with variants in 
the gene. As novel candidate genes for PME, we considered genes with two or 
more cases with variants passing the filtering in the recessive approach. In 
the dominant/de novo approach, we used a threshold of four genes. We used 
the higher threshold, since not having parental exomes lead to a substantially 
higher number of candidate genes passing the dominant/de novo filtering, 
making the analysis of genes with low patient count unfeasible. 
 In the prioritisation of candidate genes for follow-up, we considered the 
following factors. We gave less priority to highly polymorphic genes in the 
general population using a score evaluating the tolerance of genes for 
functional variation (Petrovski et al. 2013) and applying a list of 
hyperpolymorphic genes identified by others (Fuentes Fajardo et al. 2012). 
We also utilised information on the gene function, which was annotated by 
literature search and the Uniprot database (http://www.uniprot.org/; The 
UniProt Consortium (2014)), and expression pattern (GTEx, 
http://www.gtexportal.org/home/; Lonsdale et al. (2013)). Finally, to 
establish the causal role of the gene in the disease, we performed segregation 
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analysis of variants in available family members, and functional assays (see 
section 4.3). 
4.2.10 Analysis of copy number variants from genome-wide single-
nucleotide polymorphism data (III) 
In study III, Illumina Human CoreExome single-nucleotide polymorphism 
array with 548,000 markers was used in the family trio to detect CNVs from 
genomic DNA isolated from peripheral blood of the proband. PennCNV was 
used to call CNVs (http://www.openbioinformatics.org/penncnv/; Wang et 
al. (2007)). 
4.3 Functional studies of identified variants (I-III) 
We collaborated with a research group in each study to assess the 
pathogenicity of the identified candidate variants in three different genes: 
KCNC1 (study I: H. Lerche lab, University of Tübingen, Germany), UBA5 
(study II: M. Komatsu lab, Niigata University, Japan) and ADAM22 (study 
III, M. Fukata lab, National Institute for Physiological Sciences, Okazaki, 
Japan).  
As an exception, in study II the author performed analysis of RNA level 
consequences of UBA5 variants in two patients (A-4 and B-3) with biallelic 
UBA5 variants. Briefly, total RNA was extracted from primary skin 
fibroblasts of the patients. RNA was converted to complementary DNA 
(cDNA) and reverse transcription polymerase chain reaction (RT-PCR) was 
used to amplify cDNA at mutation sites. PCR products were subjected Sanger 
sequencing to determine variant genotypes in the RNA level. Additionally in 
patient A-4, UBA5 cDNA was analysed for splicing defects. RT-PCR with 
primers targeted to exons 1 and 3 were used to analyse the effect of c.164G>A 
on exon 2 splicing. PCR products extracted from agarose gel were subjected 
to Sanger sequencing. 
Detailed methodological descriptions of the methods used in the 
functional analysis are presented in the original publications I-III.  
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5 RESULTS AND DISCUSSION 
5.1 Identification of a new major subtype of progressive 
myoclonus epilepsies and broadening the genetic 
and phenotypic spectrum of known disease genes 
(I) 
5.1.1 A likely genetic diagnosis was reached in 31% of cases 
WES produced on average 4.15 gigabases of sequence per patient in exonic 
target regions, corresponding to an average sequencing coverage of 81 reads 
per nucleotide. On average 92% of targeted regions were captured with at 
least ten reads, which allowed a solid basis for variant calling in most 
regions. 
We analysed the exome data under recessive and dominant/de novo 
inheritance models and categorised candidate variants using a three-tier 
classification scheme where likely and confidently disease-causing variants 
were annotated as probably pathogenic and pathogenic, respectively. 
Altogether, we molecularly solved 26 out of 84 cases in the cohort (31.0%). 
Of the solved patients, 15 had variants in previously established disease genes 
(see section 5.1.2), and 11 in a gene where variants have not previously been 
linked to human disease (see section 5.1.3).  
The vast majority of previously molecularly diagnosed PME cases have 
autosomal recessively inherited variants (Franceschetti et al. 2014). 
Surprisingly, more than half of the solved cases in our study were due to de 
novo or autosomal dominantly inherited variants (12 de novo, 2 autosomal 
dominantly inherited and 12 autosomal recessively inherited; I, Figure 1b). 
No likely pathogenic variants were identified in mtDNA. The findings are 
presented in detail in the following sections 5.1.1-5.1.5 and in the original 
publication (I). 
5.1.2 Variants in previously established disease genes expand the 
genotypic and phenotypic spectrum of PMEs 
We first analysed the exome sequencing data for recessive and dominant/de 
novo variants in previously established PME, epilepsy and 
neurodegenerative disease genes. Using the variant classification scheme 
similar to that proposed by ACMG (Richards et al. 2015), variants in 12 cases 
were interpreted as pathogenic and in three cases as probably pathogenic 
(Table 4; see also I, Table 2). Of these cases, 12 had autosomal recessive, 
two de novo and one autosomal dominant variants. Clinical details, pedigrees 
and segregation data as well as conservation of the new variants are 
presented in the supplementary data of the original publication. 
Identification of variants in known disease genes expands both the clinical 
and genotypic spectra of PMEs, and highlights the utility of WES as a 
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diagnostic tool in a heterogeneous sample collection. Out of the total 17 
variants interpreted either pathogenic or probably pathogenic, seven were 
novel disease variants. Of the fifteen cases with pathogenic variants in known 
disease genes, ten had variants in genes specifically linked to PMEs. Notably, 
seven of these cases had an atypical clinical presentation. For example, all 
three cases with compound heterozygous variants in NEU1 did not have all or 
any of the signs of retinal impairment considered as a key clinical marker for 
NEU1 deficiency (sialidosis). Indeed, recently there has been a report of 
other similar cases who do not have all clinical signs considered to be 
pathognomonic for sialidosis (Canafoglia et al. 2014). Other examples of 
atypical presentations are two of the three Lafora disease cases, who present 
with a milder phenotype than is typically reported. One of the cases is still 
alive at the age of 42, while Lafora disease patients generally die before the 
age of 25 after deteriorating rapidly (Jara-Prado et al. 2014).  
We identified pathogenic or probably pathogenic variants in three known 
disease-related genes, where PME has not been considered as part of the 
clinical spectrum. One case had a previously reported pathogenic PRNP 
variant which causes Gerstmann-Sträussler-Scheinker disease, one of the 
inherited prion diseases characterized by progressive adult-onset ataxia and 
dementia (Hsiao et al. 1989). The variant was likely inherited from similarly 
affected and deceased father, from who we did not have DNA for segregation 
analysis. While PME has not been associated with chronic prion diseases, 
seizures, including myoclonic seizures, have been reported cases with 
Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker disease 
(Brown et al. 1986; Young et al. 1997; Bianca et al. 2003). In two cases, we 
identified compound heterozygous variants in SACS that we interpreted as 
probably pathogenic. Autosomal recessive variants in SACS cause childhood-
onset spastic ataxia, initially described clinically relatively homogenous. 
However, atypical and late-onset forms of the disease, including reports of 
seizures, have recently been described (Baets et al. 2010; Synofzik et al. 
2013). Two of the three SACS variants identified in this study have been 
previously reported in individuals with ataxia. Finally, in one patient, we 
interpreted a homozygous missense variant in TBC1D24 as probably 
pathogenic. A remarkable degree of clinical heterogeneity has been 
associated with biallelic variants in TBC1D24. Disorders linked to the gene 
include various forms of epilepsies including infantile myoclonic epilepsy, a 
multi-organ syndrome DOORS, and nonsyndromic deafness (Corbett et al. 
2010; Falace et al. 2010; Afawi et al. 2013; Guven and Tolun 2013; Milh et al. 
2013; Campeau et al. 2014; Rehman et al. 2014). Our case, who has brain 
imaging findings similar to other TBC1D24 cases, suggests that PME may be 
added to the list of TBC1D24 associated disorders.  
Finally, we had one individual where WES helped to correct the initial 
clinical diagnosis. The patient had a heterozygous, previously reported 
missense variant in SCN1A (Harkin et al. 2007), where de novo mutations 
cause severe myoclonic epilepsy of infancy (Dravet syndrome). Initially, 
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symptoms of the patient had suggested PME as the clinical diagnosis, but 
evaluation of the further clinical course confirmed this case is indeed 
presenting with Dravet syndrome. 
Table 4. Previously established disease genes with pathogenic or probably 
















Disease linked to 
the gene 
NEU1  3 3 1 AR  Yes PME (sialidosis)  
NHLRC1  2 1 1 AR  Yes PME (Lafora 
disease)  
AFG3L2  2 2 2 AR  Yes Ataxia/Spastic 
ataxia with PME  
SACS  22 NA 1 AR  No Spastic ataxia  
EPM2A  1 1 1 AR  Yes PME (Lafora 
disease)  
CLN6  1 0 1 AR  Yes PME (Neuronal 
ceroid 
lipofuscinosis)  
SERPINI1  1 0 - De novo  Yes PME with 
dementia 
TBC1D24  12 NA 1 AR  No Many neurological 
diseases including 
epilepsies 
PRNP  1 NA - AD No Prion diseases  
SCN1A  1 NA - De novo  No Severe myoclonic 
epilepsy of infancy 
PME, progressive myoclonus epilepsy; AR, autosomal recessive; NA, not applicable; AD, 
autosomal dominant 
1Applies to individuals with variants in genes previously linked to PMEs. 
2Variants were classified as probably pathogenic 
5.1.3 Analysis of heterozygous variants identified a recurrent de novo 
mutation c.959G>A (p.Arg320His) in KCNC1 as a worldwide 
cause of progressive myoclonus epilepsy 
To identify new PME genes among cases without pathogenic variants in 
known disease genes (n=69), we analysed the exome variant data for rare 
potentially deleterious recessive variants and novel heterozygous variants (de 
novo or autosomal dominantly inherited) in genes previously not established 
in human disease.  
Since the majority of cases were sporadic with only two unsolved cases 
from ‘dominant’ families after the analysis of known genes in the cohort, we 
hypothesised that any underlying pathogenic heterozygous variants would 
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mostly be de novo. However, since parents were not exome sequenced, we 
could not assess de novo mutations directly from the variant data. As an 
alternative approach, we included potentially deleterious heterozygous 
variants absent from population variant databases. We ranked the genes 
based on the number of PME cases with qualifying variants in that gene. 
The highest number of cases with variants in a single gene passing the 
filtering was 11. This number was reached for KCNC1 and TTN, but the latter 
gene was ruled out from follow-up given that it is highly polymorphic 
(longest coding region of all human genes) and associated to muscle 
disorders. We focused on KCNC1, where, remarkably, all cases were 
heterozygous for the same missense variant c.959G>A (variant nomenclature 
based on Ensembl transcript ENST00000265969.6), corresponding to 
p.Arg320His on the protein level. KCNC1 encodes potassium voltage-gated 
channel (KV) subfamily C member 1 (official symbol KCNC1, also known as 
KV3.1 which is used here). 
We analysed segregation of the c.959G>A variant in eight families with 
DNA available and the variant occurred de novo in all (I, Figure 2a), 
strongly suggesting it is pathogenic. Interestingly, one index case positive for 
the variant in KCNC1 had an affected sibling and two affected children who 
all had the variant (I, Figure 2a). Since the parents of the index case were 
healthy and negative for the variant, it suggests that one of the parents is a 
germline mosaic.  
Additionally, we screened a secondary cohort of 28 individuals for the 
KCNC1 variant. Two additional cases were identified and in one of them, we 
were able to analyse the parents; the variant occurred de novo also in this 
patient. In total, we identified 16 patients from 13 unrelated families with the 
variant. 
After the initial study (I), we have identified one Italian parent-offspring 
pair with the c.959G>A variant in KCNC1, becoming thus the second familial 
case (K. Oliver et al. unpublished data). In addition, we have become aware 
of three individuals genotyped in other laboratories in Poland, Italy and USA 
(Figure 11). 
To estimate the mutation rate of c.959G>A in KCNC1, we used a recently 
developed method that takes into account the local sequence context at the 
mutation site when estimating the mutation rate of any given single-
nucleotide substitution (Samocha et al. 2014). The rate was estimated to be 
1.75  10-7 mutations per person, which equals to one mutation in every 
5,700,000 conceptions. The estimated rate is typical for mutations occurring 
at CpG dinucleotide sites, the mutation hotspots of the genome, while the 
average de novo mutation rate is lower, 1.20×10 per nucleotide per 
generation (Kong et al. 2012) (see below section 5.1.3.3 for discussion of the 
mutation mechanism). This estimate suggests that the mutation potentially 
affects hundreds of individuals globally. Our observations of the number of 
KCNC1 mutation positive individuals in Italy, where a multicenter 
collaboration between epilepsy clinics has been established (Franceschetti et 
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al. 2014), support this estimate. As of February 2016 we have identified six 
Italian cases, while based on the mutation rate estimate and the population 
size of Italians the total number of patients in Italy should be ~10. 
 
Figure 11 The world map of patients with the recurrent c.959G>A mutation in 
KCNC1. Red pins indicate unrelated patients identified in study I (n=13), blue pins those 
diagnosed after the publication (n=4). Map modified from http://www.vectorworldmap.com/. 
5.1.3.1 Arg320His has a dominant-negative effect on KV3.1 channel 
function 
The p.Arg320His substitution occurs in a highly conserved voltage-sensing 
segment of the KV3.1 potassium channel (I, Figure 2b,c). The four in silico 
methods used predicted it to be deleterious. 
To study the consequence of the variant to KV3.1 channel function, we 
collaborated with H. Lerche’s research group in University of Tübingen, 
Germany. The mutated KV3.1 was analysed in Xenopus laevis (African clawed 
frog) oocytes, of which large size makes it a convenient system to injection of 
recombinant RNA and to measure ion channel currents by a patch clamp 
technique (Tammaro et al. 2009). Another factor explaining the wide use of 
Xenopus oocytes in basic studies of ion channel function is the lack of 
significant contamination from endogenous expression of ion channels.  
Analysis of Arg320His KV3.1 channel revealed that it does not produce 
almost any potassium currents when expressed alone in Xenopus oocytes. On 
the contrary, the wild-type channel generated strong currents upon 
membrane repolarisation (I, Figure 3a,b). To mimic the conditions in 
patient cells, next, the coexpression of mutant and wild-type channels in 1:1 
ratio was examined. An approximately of 80% reduction in potassium 
currents was observed, indicating a dominant-negative effect for the mutant 
(I, Figure 3d,e). KV3.1 and other voltage-gated potassium channels function 
as tetramers consisting of four subunits (see the next section 5.1.3.2 of more 
detailed coverage of KV3.1 function). Dominant-negative mutations in these 
genes have the capability of suppressing the function of the wild-type 
subunits (Hübner and Jentsch 2002). Finally, the experiments in Xenopus 
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oocytes suggested that the reduced currents of the mutant KV3.1 channel 
(coexpression of mutant and wild-type) exhibit altered gating properties by 
showing a hyperpolarising shift in the activation curve (opens at more 
negative voltages) (I, Figure 3f). However, the practical importance of this 
alteration is likely to be low in relation to the large reduction in potassium 
currents. 
In this study, we did not test whether trafficking of the mutant KV3.1 
channels to cell surface is affected, as has been showed for other mutant KV 
channels (e.g., Zhao et al. 2013). This should, however, be tested in cells of 
mammalian origin, since trafficking of ion channel subunits occurs in a 
different fashion in Xenopus oocytes, which could affect the results 
(Tammaro et al. 2009). 
5.1.3.2 Dysfunction of the KV3.1 channel may cause decreased 
neuronal inhibition 
KCNC1 encodes KV3.1, which functions as a highly evolutionarily conserved 
K+ channel subunit that belongs to the KV3 subfamily of tetrameric voltage-
gated K+ channels (KV3.1–KV3.4, encoded by genes KCNC1–KCNC4) (Ried et 
al. 1993). KV3.1 has two isoforms, Kv3.1a and Kv3.1b, which differ in the 
cytoplasmic C-terminal domain. The isoforms have identical biophysical 
properties but different subcellular localisation (Gu et al. 2012). Variants in 
KCNC1 have not been associated with human disease until now, but 
autosomal dominantly inherited or de novo missense variants affecting the 
highly homologous KV3.3 subunit cause spinocerebellar ataxia 13 (Waters et 
al. 2006; Figueroa et al. 2010; Figueroa et al. 2011; Németh et al. 2013). 
Numerous other voltage-gated potassium channels are also linked to human 
disease affecting CNS and other tissues, highlighting their importance for 
many biological functions (reviewed by Tian et al. (2014)). 
KV3 channel subunits can assemble heterotetramers in heterologous 
expression systems, and this may also occur in brain as subunit expression 
patterns overlap (Rudy and McBain 2001). KV subunits consist of six 
membrane-spanning segments (S1–S6). S4 forms the main voltage sensor 
where positively-charged residues, in particular four arginine residues 
occurring every third position, contribute to the gating charge (Aggarwal and 
MacKinnon 1996; Seoh et al. 1996). The PME-causing p.Arg320His 
substitution in KV3.1 affects the last of these four arginine residues (I, 
Figure 2b,c). Highlighting the functional significance of the voltage-sensor, 
numerous pathogenic variants in the S4 segment of potassium, sodium and 
calcium ion channels, have been described in various neurological and 
muscle disorders (Cannon 2010; Delemotte et al. 2010). 
Since KV3 subunits are able to assemble with each other, it is likely that 
the dominant-negative p.Arg320His in KV3.1 disrupts all KV3-mediated 
currents where it is expressed. Studies on mouse models of the KV3 family 
members suggest that they are functionally redundant. Kcnc1 and Kcnc3 
knockout mice present with relatively mild phenotypes, whereas double 
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mutant mice show prominent symptoms, including myoclonus, tremor, and 
gait ataxia (Ho et al. 1997; Joho et al. 1999; Espinosa et al. 2001). Thus, the 
effect of the dominant-negative KV3.1 and KV3.3 mutations seems to be 
comparable to that of the double knockout. Despite similar functions of KV3.1 
and KV3.3, the associated phenotypes are different: myoclonic seizures 
dominate in KV3.1 dysfunction caused by p.Arg320His and ataxia is the 
primary phenotype of the mutated KV3.3 channel, even though KCNC3 
positive patients with seizures have also been reported (Waters et al. 2006; 
Figueroa et al. 2010; Figueroa et al. 2011). Differences in the symptoms likely 
reflect the distinct expression patterns and biophysical characteristics of the 
channels (Rudy and McBain 2001). 
Voltage-gated potassium channels are transmembrane proteins that have 
a critical function in transmitting electrical signals, i.e., action potentials, 
along CNS neurons. They open and close as response to changes in 
transmembrane potential and return the depolarized cell to the resting state 
by allowing K+ ions move out of the cell. KV3 channels have a specific 
function as the determinants of high-frequency firing of action potentials in 
several types of CNS neurons, owing to their positively shifted voltage-
dependent activation and capability to activate and deactivate at higher rate 
than other KV channels (Rudy and McBain 2001). KV3.1 protein is primarily 
expressed in the CNS, a subpopulation of T lymphocytes being an exception 
(Gan and Kaczmarek 1998). It is expressed in specific fast-spiking neuron 
populations in several brain regions. Within the neurons, it can be localised 
in somata, axons and terminals (Sekirnjak et al. 1997; Ozaita et al. 2002). 
Notably KV3.1 has high expression in inhibitory GABAergic interneurons 
(Gan and Kaczmarek 1998; Rudy and McBain 2001). Interneurons are 
typically local-circuit neurons that pass information between other neurons 
(Markram et al. 2004). They are mostly inhibitory because they generally use 
GABA as a neurotransmitter. Given the important role of KV3.1 in cortical 
interneurons, we hypothesise that decreased inhibition of neuronal activity 
would result from the p.Arg320His substitution in KV3.1 due to impaired 
firing of fast-spiking inhibitory GABAergic interneurons (Figure 12). This 
mechanism is likely to increase neuronal excitation and predispose to 
myoclonus and tonic-clonic seizures seen in the patients. As mentioned in 
section 2.4.3, failure of inhibitory control in the CNS has been suggested to 
contribute to other forms of epilepsies as well (Yu et al. 2006).  
Supporting our hypothesis of decreased inhibition as the underlying 
epileptogenic mechanism of KV3 channel dysfunction, increased cortical 
excitability and susceptibility to seizures in Kcnc2 knockout mouse has been 
proposed (Lau et al. 2000) to result from the suppression of inhibitory 
interneurons. Kcnc1 knockout mice do not show increased seizure activity 
(Ho et al. 1997) but exhibit impaired motor skill (Ho et al. 1997) and altered 
oscillations recorded at the somatomotor cortex (Joho et al. 1999). 
Furthermore, impaired function of cerebellar neurons, where KV3.1 is 
expressed (Gan and Kaczmarek 1998) is likely to contribute to the motor 
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impairment. In vivo model systems are required to assess the consequence of 
p.Arg320His on neuronal and network physiology and motor function. 
Activation of KV3 channel function would be a potential therapeutic 
approach in patients with KCNC1 mutations. Interestingly, a UK-based 
biotechnology company Autifony Therapeutics Ltd. has developed 
compounds acting as positive modulators of the KV3.1 channels (Alvaro and 
Marasco 2013; Rosato-Siri et al. 2015; Taskin et al. 2015). One of these 
molecules is currently on phase IIa clinical trial in the treatment of tinnitus 
and one on phase I trial in the treatment of schizophrenia. We are currently 
collaborating with the company to assess the effect of these compounds on 
the mutant KV3.1 channel.  
Importantly, KV3.1 was recently established as the predominant voltage-
gated K+ channel in adult neural precursor cells, involved in neurogenesis of 
adult brain (Yasuda et al. 2013). KCNC1 gene knockdown with specific small 
interfering RNAs in adult neural precursor cells decreased neural precursor 
cell proliferation and neuronal differentiation. Hence, the authors suggested 
that selective KV3.1 activation could be a potential therapeutic approach for 
neurodegenerative diseases. Our observation of KV3.1 dysfunction causing a 
neurodegenerative disease provides a direct target to test this hypothesis.  
 
Figure 12 A cartoon of the underlying mechanisms of progressive myoclonus 
epilepsy caused by a de novo mutation KCNC1. Mutations (lightning bolts) hit the same 
nucleotide in KCNC1 and disrupt the function of a brain-expressed potassium ion channel, 
which causes a severe form of epilepsy due to decreased inhibition. A potential therapeutic 
approach is to use newly identified compounds to activate the KV3.1 potassium channel. 
5.1.3.3 Why the c.959G>A mutation in KCNC1 is recurrent and why we 
have not observed any other changes in KCNC1? 
As mentioned above, the identification of de novo mutations as a cause of 
approximately half of the solved PME cases in the exome sequencing cohort 
was unexpected, given that the vast majority of previously established causes 
of PME have shown autosomal recessive inheritance (Franceschetti et al. 
 
73 
2014). An even more surprising observation was that a single de novo 
mutation in KCNC1 underlies 13.0% of the exome cohort. Notably, no other 
pathogenic changes have been observed to date in the gene, while four 
additional cases with the recurrent c.959G>A have been identified after 
publication of study I.  
Observing recurrent mutations in epilepsies or other neurological 
diseases is not a rare phenomenon (Ducros et al. 1999; Kearney et al. 2006; 
Wagnon and Meisler 2015) but reports of diseases where the vast majority 
cases are caused by a single variant occur substantially less often (e.g., 
Simons et al. 2013). This phenomenon of a single, highly recurrent mutation 
explaining the majority of or all cases has been reported in association with 
distinguishable syndromes including achondroplasia (mutated gene FGFR3) 
(Rousseau et al. 1994; Shiang et al. 1994), Muenke syndrome (FGFR3) 
(Bellus et al. 1996), Apert syndrome (FGFR2) (Wilkie et al. 1995), and 
Hutchinson-Gilford progeria syndrome (LMNA) (Eriksson et al. 2003).  
At least two factors may account for the recurrent occurrence of c.959G>A 
mutation in KCNC1. First, the mutation occurs in a CpG dinucleotide, which 
are known mutation hotspots (Kong et al. 2012) due to the spontaneous 
deamination of methylated cytosines to thymine (Pfeifer 2006). Notably, the 
recurrent mutations in the above mentioned syndromes occur in CpG sites.  
Second, KCNC1 mutations other than c.959G>A may cause a phenotype 
different from PME. This might be the single most important explanation 
why no other mutations have been observed in our PME cohort. This 
hypothesis is supported by observations in ataxia caused by mutations in 
KCNC3. In the case of KCNC3, missense changes encoding p.Arg420His and 
p.Arg423His in the S4 segment of the KV3 channel subunit (I, Figure 2c) are 
associated with different clinical manifestations, late-onset progressive ataxia 
and early-onset slowly progressive ataxia, respectively (Figueroa et al. 2010). 
The effects of these mutations on KV3.3 channel function are distinct 
(Minassian et al. 2012; Zhao et al. 2013), and the amino-acid specific 
consequences of mutations occurring in the voltage-sensor segment can be 
generalised to other voltage-gated potassium channels as well (Seoh et al. 
1996). The more severe consequence of p.Arg423His in KCNC3, which is 
occurs in a position analogous to the PME-causing substitution p.Arg320His 
in KCNC1, is likely due to both a dominant-negative suppression of current 
amplitude and a dominant gain-of-function effect on channel gating 
(Minassian et al. 2012), similarly than we showed in this study for 
p.Arg320His in KCNC1. Notably, a recurrent occurrence of both the 
p.Arg420His (Waters et al. 2006; Figueroa et al. 2010) and p.Arg423His 
(Figueroa et al. 2010; Figueroa et al. 2011) mutations in KCNC3 has also 
been reported. Indeed, the S4 segments of voltage-gated ion channels 
contain highly conserved and essential positively charged arginines encoded 
by CpG containing codons, and therefore it is not surprising that S4 segment 
arginine mutations underlie also several other channelopathies (Cannon 
2010; Delemotte et al. 2010).  
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Finally, one explanation for the lack of other identified pathogenic 
variants in KCNC1 could be that other missense variants or loss-of-function 
changes in the gene are mostly tolerated. However, this is likely not the case, 
because KCNC1 is among the top 1% least tolerant genes for functional 
variation (Samocha et al. 2014; Lek et al. 2015), suggesting that variants 
throughout the gene have phenotypic consequences. To conclude, observing 
c.959G>A as the sole KCNC1 mutation in our study may be primarily because 
other mutations in the gene have slightly different biophysical consequences 
and the resulting phenotype would not meet all diagnostic criteria for PME. 
To study the mutation mechanism of the recurrent c.959G>A mutation in 
KCNC1, we are currently assessing the parent of origin of the mutation. 
Preliminary data from two individuals shows that in one patient the 
mutation originated from the mother and in one from the father (M. Muona, 
unpublished data), suggesting that mutations do not occur at least 
exclusively in males. Notably, mutations in the above-mentioned syndromes 
caused by single mutations in CpG sites occur exclusively in fathers (Glaser 
and Morison 2009). In diseases showing a more diverse mutational 
spectrum, such as Dravet syndrome, majority, but not all, of the de novo 
variants are of paternal origin (Heron et al. 2010). In general, the majority of 
de novo variation arises in males, the number of de novo variants increasing 
along with father’s age (Kong et al. 2012). Indeed, spermatogenesis involving 
a higher number of cell divisions is more susceptible to point mutations 
compared to oogenesis. Furthermore, the exclusive occurrence of 
achondroplasia and Apert syndrome mutations in males, is at least partially 
explained by the observation that spermatogonial stem cells with the 
recurrent mutations have a proliferative advantage over unmutated cells 
(Goriely et al. 2003; Shinde et al. 2013).  
5.1.3.4 Myoclonus epilepsy and ataxia due to potassium channel 
mutation (MEAK) resembles clinically the most common form 
of progressive myoclonus epilepsy 
We proposed the newly identified form of PME to be termed as myoclonus 
epilepsy and ataxia due to potassium channel mutation (MEAK). The main 
clinical features of the 16 MEAK patients identified in study I are shown in 
Table 1 of the original publication. Briefly, the first symptoms, which are 
usually myoclonic seizures, emerged at ages of 5–14 years. Myoclonus 
typically became debilitating during adolescence. Ataxia is observed in all. 
Learning disability and cognitive decline was noted in some cases. MRI 
findings were normal or show cerebellar atrophy. Premature death has not 
been observed. The oldest known MEAK case, identified after the initial 
publication, is now 63 years of age. Clinical presentation was somewhat 
milder in the family where the mutation was transmitted from the affected 
mother to offspring (I, Figure 2a). However, in most cases the phenotype is 
severe, explaining why the mutation occurs primarily de novo. 
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Interestingly, MEAK has substantial clinical overlap with ULD, the most 
common form of PME, highlighting the importance of being able to perform 
a molecular diagnosis in these diseases. The most apparent difference in the 
clinical presentation between ULD and MEAK is that the clinical course of 
MEAK is typically more severe, with patients requiring a walking aid by their 
teens, whereas ULD patients more often remain ambulant with the disorder 
stabilizing in middle age (Magaudda et al. 2006).  
Given that the underlying molecular biology for these two forms of PME 
appears quite different, it is intriguing to see clinical overlap between them. 
ULD, which is autosomal recessively inherited, is caused by mutations in the 
gene encoding cystatin B (CSTB), a cysteine protease inhibitor with roles 
implicated in apoptosis, oxidative stress and inflammation (Pennacchio et al. 
1998; Lehtinen et al. 2009; Tegelberg et al. 2012; Okuneva et al. 2015). 
Recent evidence suggests that altered GABAergic signaling contributes to the 
pathogenesis in Cstb knockout mice (Buzzi et al. 2012; Joensuu et al. 2014), 
which may underlie hyperexcitability predisposing to myoclonus and 
seizures. Moreover, loss of GABAergic neurons have been observed in the 
mouse model for Lafora disease (Ortolano et al. 2014). These observations 
suggest a possible convergent pathway for PMEs associated with variants in 
different genes.  
5.1.4 Exome variant data of unsolved patients contain genes of 
potential interest for further research 
We did not identify any candidates as new recessive disease genes using our 
criteria of observing variants in a gene in at least two cases under the 
recessive approach (I, Figure 1a). Five genes with qualifying variants in two 
or more unsolved PME cases were identified but they were excluded as new 
epilepsy genes since the genes were, for example, highly polymorphic, linked 
to muscle disorders and/or not expressed in the CNS (I, Supplementary 
Table 7). 
To identify potential disease genes for further research, we analysed the 
variant data for biallelic loss-of-function variants (nonsense, canonical splice 
site, frameshift indel). We observed nine such genes in single cases (I, 
Supplementary Table 8). Out of these, we considered ALG10 and 
APOA1BP in particular as genes of potential interest as they encode 
functionally conserved proteins expressed in the CNS. These genes are 
among those where we are actively looking for additional cases through 
collaboration, including the GeneMatcher data sharing platform. 
Identification of a second, independent hit in another patient, followed by 
functional studies, would be the next steps of establishing them as new 
disease genes. 
In the analysis to identify novel dominant/de novo genes other than 
KCNC1, we observed 14 genes with potential variants in four or more patients 
who did not have the c.959G>A mutation in KCNC1 or mutations in known 
disease genes (I, Supplementary Table 2). However, we did not consider 
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any of the genes as likely true PME disease genes for similar reasons 
described above for the excluded recessive genes. In addition, we discarded 
some of the genes, since variants were inherited from unaffected parents in 
the segregation analysis. Since there were 425 genes with two to three cases 
with variants passing the filtering, we were not able to pinpoint obvious novel 
genes in this category. 
5.1.5 Ways to dissect still unsolved PME cases 
Overall, we solved 31.0% of the study cohort, thus reducing the proportion of 
molecularly undiagnosed PME cases, which is estimated to be 28% in the 
Italian population (Franceschetti et al. 2014). The success rate is in line with 
several other WES studies aiming to elucidate the underlying genetic causes 
in various rare disorders (Iglesias et al. 2014; Srivastava et al. 2014; Yang et 
al. 2014; Retterer et al. 2015; The Deciphering Developmental Disorders 
Study 2015; Helbig et al. 2016; Powis et al. 2016).  
Two-thirds of the cohort remained without a molecular diagnosis. The 
unsolved patients were heterogeneous in terms of age of onset and associated 
clinical features, as were the solved cases. Family history of the unsolved 
cases is also heterogeneous and includes 50 sporadic cases (50/70, 71%), 
seven cases from recessive families (7/11, 64%), and one case from dominant 
families (1/3, 33%) (I, Figure 1b). 
Given that we now established an important role for de novo mutations in 
PMEs, we are next performing WES in trio setting for unsolved cases. This 
approach has been successful in many other epilepsy WES studies (e.g., 
Epi4K Consortium and Epilepsy Phenome/Genome Project 2013; 
EuroEPINOMICS-RES Consortium et al. 2014). This study was limited to 
coding regions of the human genome, and even there coverage was not 
complete since ~8% of the exome was captured with less than 10 reads. It is 
likely that WGS would solve some proportion of the remaining individuals, 
which has been the case in, for example, intellectual disability (Gilissen et al. 
2014). We also did not assess CNVs or variants showing di- or polygenic 
inheritance. Preliminary analysis of the current exome sequence data for 
CNVs indicates that the data do not contain CNVs in known epilepsy genes, 
while exome-wide investigation of CNVs remains to be carried out (M. 
Muona, unpublished data). Finally, it is likely that pathogenic variants in 
some proportion of the unsolved individuals were already captured by the 
current WES data. However, the clinical significance of these variants was 
not appreciated, since they occurred in a new disease gene and in one 
individual only, or alternatively, they were discarded in the analysis pipeline 
(e.g., synonymous variants). As mentioned above, data sharing and further 
genetic studies in PMEs and related disorders may assist pinpointing further 
causal variants in the existing WES data. 
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5.2 Biallelic variants in UBA5 cause an infantile-onset 
encephalopathy (II) 
5.2.1 Analysis of in-house and external exome datasets revealed 
compound heterozygous variants in UBA5 in five families with 
similar clinical features 
As part of a WES project aiming to identify the underlying causes of 30 
Finnish individuals having severe infantile-onset epileptic syndromes, we 
analysed family A with two affected siblings (Figure 10 p. 61; II, Figure 
1B). In this family, healthy parents and the index case, assigned here as A-4, 
were sequenced. Given that the affected siblings represent both sexes, we 
primarily searched for rare, potentially deleterious autosomal recessively 
inherited variants.  
The only variants qualifying the autosomal recessive variant filtering were 
compound heterozygous variants in UBA5 (Ubiquitin-like modifier activating 
enzyme 5). One of the variants is c.1111G>A, which encodes a missense 
substitution p.Ala371Thr (variant nomenclature based on GenBank ID 
NM_024818.3). The p.Ala371Thr is relatively common in the ExAC data: 
carrier frequency is 0.92% in Finns and 0.56% in other Europeans, with no 
homozygotes, however, detected. The other variant identified in family A, 
c.164G>A, was predicted to encode an amino acid substitution p.Arg55His, 
but later analysis of UBA5 in the RNA level in patient cells showed that this 
change also affects splicing (see section 5.2.2). This variant is very rare, seen 
only once in the reference databases with one carrier in ExAC. Both variants 
occur in evolutionarily conserved sites (II, Figure 1E) and are predicted to 
be deleterious by the used in silico methods. Segregation analysis by Sanger 
sequencing showed that the variants segregate in an autosomal recessive 
manner in this family with two unaffected siblings (II, Figure 1B). 
In addition to the 30 patients sequenced at WTSI, we have exome 
sequenced and analysed in-house six additional families with severe epileptic 
syndromes and ascertained through collaboration. One of these is a family 
ascertained by clinicians in University of Oulu, Finland (denoted as family 
B). The family has four affected and six unaffected siblings born to healthy 
parents. Exome sequencing was performed for the parents, two affected 
siblings and one unaffected sibling (Figure 10, p. 61; II, Figure 1B). Also in 
this family, the only variants passing the filtering criteria of autosomal 
recessive analysis were compound heterozygous variants in UBA5. Of the two 
variants identified in this family, one was the same as an in Family A, 
p.Ala371Thr. The other was a nonsense variant c.855C>A (p.Tyr285Ter), 
occurring in exon 9 of the 11 exons of UBA5, and predicted to cause nonsense 
mediated decay making the allele dysfunctional. Sanger sequencing of the 
variants in one additional affected sibling and two unaffected siblings 
confirmed the autosomal recessive segregation of these variants in family B 
(II, Figure 1B).  
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Next, we utilised externally generated datasets to try to identify additional 
families with biallelic variants in UBA5. We accessed GeneMatcher web 
resource as well as contacted researchers at the EuroEPINOMICS Rare 
Epilepy Syndrome project (178 WES or WGS samples), Deciphering 
Developmental Disorders (DDD) study (exomes from >4,000 families with 
developmental disorders; The Deciphering Developmental Disorders Study 
2015) and Northern Finland Intellectual Disability cohort (455 independent 
exomes). In the DDD and Northern Finland Intellectual Disability exomes, 
we identified additional three unrelated individuals who are clinically similar 
to patients in families A and B and have compound heterozygous variants in 
UBA5. These three patients (C-4, D-3 and E-3) have p.Ala371Thr in trans 
with a novel or very rare nonsense variant (II, Figure 1B).  
Given that the p.Ala371Thr variant, which is present in all five families, is 
relatively common in Europeans, we assessed the probability to observe rare, 
biallelic UBA5 variants in multiple families only by chance in the analysed 
study populations. We utilised a recently established statistical tool, 
‘recessiveStats’ (Akawi et al. 2015), which can be used to pinpoint genes that 
are enriched for biallelic functional (e.g. missense, in-frame indel) and loss-
of-function variants in the study cohorts. For each protein-coding gene, the 
tool fetches the ExAC database to determine cumulative allele frequencies of 
functional and loss-of-funcion variants in the general population. By using 
the obtained frequencies recessiveStats evaluates the expected prevalence of 
biallelic genotypes in a given gene, which is then compared to that observed 
in the study. Using this tool we showed that it is highly unlikely to observe 
only by chance four (B-E) families with missense + loss-of-function UBA5 
variants (variants of family A are annotated as missense+missense) in our 
study populations (P=3.3010-10). Moreover, we accessed over 75,000 
control exomes in the ExAC, SISu and DDD studies and observed no 
individuals with p.Ala371Thr in trans with a loss-of-function variant, further 
supporting a pathogenic role for this allele combination.  
Clinical evaluation of the nine patients in five families showed substantial 
overlap. Briefly, the symptoms emerged within the first months of life with 
irritability, which was followed in most by dystonic movements, epileptic 
seizures and truncal hypotonia. The patients showed moderate to severe 
intellectual disability and stagnation of development. Patients in family B 
also had severe growth retardation. Patients showed microcephaly but MRI 
and neuropathological findings were mild and unspecific. Premature death is 
associated with the disease. Clinical features are described in more detail in 
the manuscript of study II. 
Segregation and statistical data of these rare UBA5 variants, and the 
substantial clinical overlap between the nine affected individuals in five 
unrelated families together strongly suggest that these variants are the cause 
of the newly identified syndrome. Further supporting this conclusion, we 
became aware of another research group (D. Bonneau et al., personal 
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communication) who has characterized five patients in four families with 
compound heterozygous variants in UBA5 and similar clinical presentation. 
5.2.2 Functional studies show that identified UBA5 variants have a 
hypomorphic effect on the enzymatic activity of UBA5 
We performed several experiments to elucidate the molecular consequences 
of the identified variants. UBA5 encodes an activating enzyme for UFM1, 
which is a ubiquitin-like protein (UBL) that is ligated to its target proteins 
with a covalent bond (Komatsu et al. 2004). UFM1 and other UBLs act as 
post-translational regulators that have functions in various cellular processes 
(more information of the function of the UFM1-system is presented in the 
next section 5.2.3). The first step of the activation of UFM1 by UBA5 is the 
formation of a noncovalent complex between UBA5 and UFM1 (Komatsu et 
al. 2004; Bacik et al. 2010) (II, Figure 1A). Then a thioester bond between 
the catalytically active cysteine residue 250 of UBA5 and a C-terminal glycine 
residue in UFM1 is formed. After UFM1 activation, UBA5 interacts with the 
conjugating enzyme of UFM1, UFC1, and transfers the activated UFM1 from 
UBA5 to UFC1 (Komatsu et al. 2004). Finally, UFL1 enzyme ligates UFM1 to 
its target protein (Tatsumi et al. 2010). 
First, we studied the identified UBA5 variants on the RNA level. Analysis 
of UBA5 cDNA in fibroblasts of one of the affected individuals in family A, 
showed that the c.164G>A variant predicted to cause p.Arg55His substitution 
affects in fact splicing by facilitating non-frame skipping of exon 2. Since 
skipping of exon 2 leads to a premature stop codon, the mRNA is likely 
subjected to nonsense mediated decay, which explains why UBA5 expression 
is approximately 30% lower in the patient fibroblasts (II, Figure 2A). 
However, this effect on splicing does not appear to occur with full efficiency 
leaving some transcripts normally spliced. This means that Arg55His mutant 
is expressed in patient cells at lower levels, but as shown below, it is 
nonfunctional. In fibroblasts of one patient from family B, UBA5 expression 
is 50% lower due to the fact that the other variant in this family encodes a 
premature stop codon (II, Figure 2A). Indeed, analysis of cDNA in this 
patient shows that Ala371Thr is the only allele expressed. 
Our collaborator Prof. Masaaki Komatsu’s lab has established biochemical 
assays to assess the above described function of UBA5 as the activating 
enzyme of UFM1. First, UBA5 function was tested in an in vitro thioester 
formation assay, where reactions contained recombinant proteins UBA5 
(wild-type or one of the two missense mutants Arg55His or Ala371Thr), 
UFM1 and UFC1. This assay showed that both UBA5 mutants have lower 
ability to form an intermediate with UFM1 compared to the wild-type UBA5 
(II, Figure 3C,D). In addition, neither UBA5 mutant was able to transfer 
UFM1 to UFC1 in a short 5-minute assay. When the reaction time was 
extended up to 60 minutes, Arg55His showed approximately 50% reduction 
in the ability to transfer UFM1 to UFC1, while for Ala371Thr the reduction 
was 20-30% (II, Supplementary Figure S7). The ability of UBA5 mutants 
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to activate UFM1 and transfer it to UFC1 was tested also in HEK293T cells 
depleted with endogenous UBA5. In these cells, either wild-type or mutant 
UBA5 was overexpressed together with UFM1 and UFC1. Arg55His mutant 
showed reduced ability to activate UFM1, and also formation of the UFM1-
UFC1 complex was suppressed (II, Figure 3A,B). For Ala371Thr mutant, 
the ability to activate UFM1 was not significantly reduced compared to wild-
type, but the ability to transfer UFM1 to UFC1 was weaker in comparison to 
that of the wild-type. UBA5 function was also examined in primary skin 
fibroblasts derived from two patients, one from each family. Compared to 
control fibroblasts, there were less UFM1-UBA5 and UFM1-UFC1 complexes 
in patient-derived fibroblasts (II, Figure 2B). Finally, the effect of UBA5 
mutants on UFM1-target protein conjugate formation was examined. With 
Arg55His both quantity and number of conjugates was clearly reduced, while 
for Ala371Thr the decrease was only suggestive (II, Figure 3E,F)  
As a conclusion, the biochemical experiments suggest that Arg55His 
mutant has severely attenuated ability to activate UFM1 and transfer it to 
UFC1, whereas in Ala371Thr mutant, the defect is milder. Compatible with 
the hypomorphic nature of the Ala371Thr mutant, UBA5-UFM1 and UFM1-
UFC1 intermediates are not completely absent from patient fibroblasts, 
indicating there is some UBA5 activity remaining. 
Based on the functional experiments, the nine patients in five families are 
heterozygotes for a variant of mild effect (p.Ala371Thr) and a variant of a 
severe, loss-of-function effect on UBA5 activity (combined splice and severe 
missense variant in family A and nonsense variants in families B, C, D and 
E). In other words, on the protein level the only residual UBA5 enzymatic 
activity comes from the p.Ala371Thr allele in all families. This likely explains 
the substantial clinical overlap between the families. Noteworthy, the other 
research group with UBA5 patients has identified two families of European 
origin who are genotypically similar to ours, since they have the p.Ala371Thr 
variant combined with a loss-of-function variant (D. Bonneau et al., personal 
communication). 
5.2.3 Pathomechanism of UBA5 dysfunction 
Ubiquitin and UBLs are small proteins that function as post-translational 
regulators of various cellular processes. UFM1 is a highly conserved UBL that 
can be found in all multicellular organisms. Members of the UFM1 cascade 
are ubiquitously expressed. The function of the UFM1-conjugation is, 
however, largely unknown and only two target proteins, UFBP1 and ASC1, 
have been identified (Tatsumi et al. 2010; Yoo et al. 2014). 
Highlighting their important role in a wide range of cellular tasks, genetic 
defects and/or abnormal function of members of ubiquitin and UBL 
pathways have been linked to various genetic disorders, including 
neurodegenerative and neurodevelopmental disorders, anaemia, muscular 
atrophy and growth retardation syndrome (Kishino et al. 1997; Huber et al. 
2005; Jacquemont and Taniguchi 2007; Ramser et al. 2008; Atkin and 
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Paulson 2014). Before this study, disease-causing variants in genes encoding 
proteins of the UFM1-system had not been reported to date, with the 
exception of a missense variant in UFSP2 (UFM1-specific peptidase) that 
shows suggestive association with hip dysplasia (Watson et al. 2015). 
Moreover, while the manuscript of this study was under review, Duan and 
colleagues reported one family with two siblings with childhood-onset ataxia 
and compound heterozygous UBA5 variants (p.Lys310Glu and p.Arg246Ter) 
(Duan et al. 2016). This suggests that UBA5 variants may also be linked to a 
substantially milder neurological disease in addition to the infantile-onset 
encephalopathy described in our study. The severity of UBA5 associated 
conditions most likely correlates with the degree of remaining enzymatic 
activity of UBA5.  
Prior to genetic studies in human, the importance of the UFM1-system 
has been noted by studying mice with knocked out Uba5, Ufm1 or Ddrgk1 
(Ufbp1). All of these gene knockouts cause embryonic lethality, showing that 
UFM1-system function is indispensable for normal development (Tatsumi et 
al. 2011; Cai et al. 2015). Furthermore, studies have shown that the UFM1-
system is crucial for erythroid development, breast cancer development and 
endoplasmic reticulum (ER) stress response (Lemaire et al. 2011; Tatsumi et 
al. 2011; Zhang et al. 2012; Yoo et al. 2014). However, the function of the 
UFM1 system has not been assessed in the CNS.  
In this study, we were able to analyse the function of the UFM1-system in 
the CNS by studying mice with a CNS-specific knockout of Ufm1 that was 
generated using Cre-Lox recombination (II, Figure 4). The mice died within 
one day after birth. Neuropathological examinations of the brain of the Ufm1 
mice did not show major irregularities in cellular organization but the brains 
were microcephalic. Interestingly, neurons in the occipital region of the brain 
showed increased apoptosis. Findings in mice lacking Ufm1 in the CNS were 
similar to those observed in UBA5 patients, who also had microcephaly but 
major abnormalities in brain structure were absent. In conclusion, results 
from the mice lacking Ufm1 in the CNS show that UFM1-system has an 
important role for normal CNS development and cell survival. 
Observation of apoptosis in the Ufm1 mouse neurons is intriguing, since 
silencing of the UFM1-system has been shown to increase ER stress induced 
cell death in pancreatic beta cells and hematopoietic stem cells (Lemaire et 
al. 2011; Cai et al. 2015). In normal conditions, ER takes care of protein 
folding and the properly folded proteins are transported to the Golgi 
apparatus (Ozcan and Tabas 2012). However, certain stimuli, such as 
hypoxia, oxidative injury or some chemicals, may induce ER stress, which is 
a condition where the normal ER homeostasis is altered, and unfolded 
proteins accumulate in the ER. Normally, cell copes with this stress by 
increasing folding capacity of proteins and inhibiting protein translation. 
This is called the ER stress response or unfolded protein response. However, 
prolonged or excessive ER stress can trigger cell death. Also, genetic defects 
disrupting components of the ER stress response pathway may induce cell 
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death and be involved in various human diseases, including 
neurodegenerative diseases (Zhao et al. 2005; Ozcan and Tabas 2012).  
Given the suggested role of the UFM1-system to protect cells from ER 
stress mediated cell death, it is therefore tempting to hypothesise that in our 
patients reduced UBA5 activity causes diminished conjugation of UFM1 to its 
target proteins, which impairs ER stress response and leads to excessive cell 
death, in the CNS in particular (Figure 13). Further studies are warranted to 
test this hypothesis about the pathomechanism of the UBA5 associated 
syndrome. Already now, the other group with UBA5 families has observed 
that ER stress response is indeed altered in fibroblasts of patients with 
biallelic pathogenic variants in UBA5 (D. Bonneau et al., personal 
communication). Finally, a knock-in mouse expressing the mouse analogue 
for the human p.Ala371Thr variant of UBA5 would be of high value in 
dissecting the molecular consequences of the attenuated UFM1-system.  
 
Figure 13 A schematic of the hypothetical pathomechanism of UBA5 dysfunction. In 
wild-type cells, UBA5 activates UFM1 robustly and transfers UFM1 to UFC1. Upon 
endoplasmic reticulum (ER) stress induction, this pathway protects cell from ER stress 
induced apoptosis. In patient cells, UBA5 population is reduced in both quantity and catalytic 
activity, and consequently, UFM1 activation and transfer of UFM1 to UFC1 occurs less 
efficiently. Consequently, the number of UFM1-target protein conjugates is reduced, which 
predisposes to ER stress mediated apoptosis. The figure is modified from Figure 1A (study 
II), which was created by Masaaki Komatsu. 
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5.3 Loss-of-function of ADAM22 implicated in rapidly 
progressing encephalopathy with epilepsy and 
cortical atrophy (III) 
5.3.1 Analysis of whole-exome sequencing data revealed compound 
heterozygous variants in ADAM22 
Like family A in study II, an affected individual with rapidly progressing 
encephalopathy with epilepsy and cortical atrophy was sequenced as part of 
the WES project consisting of 30 Finnish individuals with severe, infantile-
onset epileptic syndromes (see original publication III for more detailed 
description of clinical features). Analysis of the WES data of the female 
patient did not reveal any candidate variants in known disease genes or in 
mtDNA. Similarly, analysis of genome-wide SNP data for CNVs in the 
parent-offspring trio did not show any likely pathogenic changes.  
Next, we looked for novel causes by analysing the exome data for 
recessive and de novo variants. However, parents of the patient were not 
exome sequenced so were not able to assess de novo variants directly. 
Filtering the variant data for novel heterozygous variants yielded seven 
variants, which is a manageable number (see below for discussion about the 
ability to dramatically narrow down the number of variants in exome data 
from samples of Finnish origin). Segregation of these variants was analysed 
by Sanger sequencing and all of them turned out to be inherited from one of 
the parents. Analysis of exome data for recessively inherited variants yielded 
two genes, ADAM22 and CPA4, but only the compound heterozygous 
variants in ADAM22 segregated in an autosomal recessive manner in the 
subsequent segregation analysis done by Sanger sequencing (III, Figure 
2A). 
Of the compound heterozygous variants in ADAM22 (ADAM 
metallopeptidase domain 22), one is a missense variant c.1202G>A 
(p.Cys401Tyr) that is present in only two carriers in the ExAC database 
(mutation nomenclature based on GenBank sequence NM_021723). It is 
predicted to be deleterious by all four prediction programs used. The 
p.Cys401Tyr variant occurs in a highly conserved cysteine residue that forms 
a disulfide bond with another cysteine residue at position 394 (III, Figure 
2B,C) (Liu et al. 2009). The amino acid substitution could thus potentially 
alter the tertiary structure of the protein. The other variant in ADAM22 is a 
1bp frameshift deletion in exon 27 of ADAM22 with a total of 31 exons 
(c.2396delG, p.Ser799IlefsTer96). It is predicted to alter the last ~100 amino 
acids of the full-length 906-amino acid ADAM22 protein (III, Figure 2B). 
Both filtering approaches, “de novo” and recessive, yielded a manageable 
number of candidate variants, even though we did not exome sequence 
parents. This applies also to other Finnish exomes that we have generated in-
house. In those, we observe on average ~15 heterozygous variants per exome 
that pass the filtering for novel, potentially deleterious heterozygous variants. 
On the contrary, in non-Finnish Europeans using the same filtering criteria 
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as in this study, we see a substantially higher number (~50 on average). This 
difference indicates that variant filtering in the Finnish exomes benefits a lot 
from the comprehensive representation of Finns in the variant databases 
(3,200 Finns in ExAC and 100 in the 1000 genomes) and from the reduced 
genetic heterogeneity in the Finnish population due to past bottlenecks in the 
population history (Peltonen et al. 1999).  
We aimed to identify additional individuals with severe epileptic 
syndromes and recessive ADAM22 variants in various WES cohorts. We did 
not identify any additional cases in the in-house exomes, GeneMatcher 
database, 178 epileptic encephalopathy exomes of the EuroEPINOMICS 
project or in first ~1000 trios of the Deciphering Developmental Disorders 
project. 
5.3.2 Identified ADAM22 mutants do not bind to its ligand, LGI1 
Although we did not identify a ‘second hit’, i.e., another case with pathogenic 
ADAM22 variants, which is the prerequisite for the establishment of a new 
disease gene, we progressed with functional studies of the identified 
ADAM22 variants. This was done because ADAM22 has been under active 
research among epilepsy researchers and neurobiologists for the past decade 
as it has been recognized as the postsynaptic receptor for a secreted 
glycoprotein LGI1 (Fukata et al. 2006), where mutations cause autosomal 
dominant lateral temporal lobe epilepsy (Kalachikov et al. 2002). Moreover, 
since Adam22-/- mice present with lethal seizures (Sagane et al. 2005), we 
considered that the identified ADAM22 variants are a good candidate for the 
genetic cause of the disease in our patient. 
Our collaborators in Prof. Masaki Fukata’s lab studied whether the two 
ADAM22 mutants can bind to its two known binding partners, LGI1 and 
PSD-95, of which the latter is a postsynaptic scaffolding protein. Wild-type 
ADAM22 binds to LGI1 at the postsynaptic membrane. Interaction with PSD-
95 occurs in the cytoplasm where the C-terminal PDZ-binding motif of 
ADAM22 binds to the PDZ-domain of PSD-95 (Lovero et al. 2015). A cell-
surface binding assay indicated that neither the Cys401Tyr missense mutant 
nor the frameshift mutant is able to bind LGI1 in a heterologous expression 
system in COS7 cells (III, Figure 3A). Furthermore, immunoprecipitation 
assay in HEK293T suggested that neither mutant coimmunoprecipitates with 
LGI1 (III, Figure 3C). The frameshift mutant did not also bind to PSD-95, 
since the mutant misses the C-terminal PDZ-binding motif (III, Figure 3D). 
Taken together, these experiments suggest that both ADAM22 mutants are 
dysfunctional and cannot bind to LGI1, and in the case of the frameshift 
mutant, ability to bind to PSD-95 is also diminished. 
5.3.3 Pathomechanism of ADAM22 dysfunction 
ADAM22 is expressed at the postsynaptic membrane of certain CNS neurons 
(Fukata et al. 2006; Fukata et al. 2010; Lovero et al. 2015) (Figure 14). It is 
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also expressed in axons and peripheral nervous system (Ogawa et al. 2010; 
Özkaynak et al. 2010), but its role in the postsynaptic membrane has been 
studied most extensively. The LGI1-ADAM22 complex regulates 
development and functional maturation of synapses in early postnatal stages 
and plays a role in maintaining the brain excitability throughout the life 
(Zhou et al. 2009; Boillot et al. 2014; Lovero et al. 2015). Specifically, the 
LGI1-ADAM22 complex recruits AMPA-type glutamate receptors to the 
postsynapses, which is one of the hallmarks of excitatory synapse maturation 
(Fukata et al. 2006; Fukata et al. 2010; Lovero et al. 2015). The interaction 
between the C-terminal PDZ-binding motif of ADAM22 and the PDZ-
domains of PSD-95 is required for the regulation of the AMPA receptors 
(Lovero et al. 2015). Another hallmark of glutamatergic synapse maturation 
is the change of subunit composition of the NMDA-type glutamate receptor. 
It has been suggested that when LGI1 is mutated, the ratio of NR2B/NR2A 
subunits of the NMDA-receptor remain high, which increases the excitatory 
effect of glutamate (Zhou et al. 2009). As with AMPA receptors, the 
interaction between ADAM22 and PSD-95 regulates NMDA receptor 
function (Lovero et al. 2015). Further stressing the role of LGI1 in 
downregulation of excitation, targeted deletion of LGI1 in glutamatergic 
excitatory neurons has been shown to be sufficient to generate seizures 
(Boillot et al. 2014). Finally, highlighting the importance of LGI1-ADAM22 
complex in keeping brain excitability in balance throughout life, one form of 
autoimmune limbic encephalitis, which involves amnesia and seizures, is due 
to autoantibodies against LGI1 (Irani et al. 2010; Lai et al. 2010). This has 
been shown to cause disruption of LGI1-ADAM22 interaction and 
subsequent reduction of AMPA receptors (Ohkawa et al. 2013). Given that 
the LGI1-ADAM22 complex is also expressed in inhibitory interneurons, 
whose excitatory input is mediated by AMPA-type glutamate receptors, the 
authors suggested that reduced inhibition of neural networks due to lowered 
excitation of interneurons is one potential epileptogenic mechanisms related 
to LGI1-ADAM22 dysfunction (Ohkawa et al. 2013).  
Taken together, the LGI1-ADAM22 complex functions as an 
antiepileptogenetic factor of which dysfunction causes an imbalance of 
excitation and inhibition, either too much of excitation or too little of 
inhibition, in all stages of brain development. This is the likely mechanism 
underlying intractable seizures in our patient. Notably, the majority of 
proteins involved in this pathway, ADAM22, LGI1, ADAM23, stargazin 
(CACNG2), AMPA and NMDA receptor subunits (Figure 14) are genetically 
linked to epilepsy in mice and/or humans (Letts et al. 1998; Kalachikov et al. 
2002; Sagane et al. 2005; Owuor et al. 2009; Chabrol et al. 2010; Christie et 





Figure 14 The synaptic LGI1-ADAM22/23 complex. LGI1 is a secreted glycoprotein, 
which binds to its transmembranic receptors ADAM23 and ADAM22 at the synapses. In this 
study, functional assays with ADAM22 mutants, which harbour changes seen in the patient, 
indicated that the ability of the mutants to bind to LGI1 and PSD-95 is abolished (red cross). 
The impairment of the LGI1-ADAM22/23 complex and its interaction with PSD-95 disrupts 
development and functional maturation of synapses, where AMPA- and NMDA-type 
glutamate receptors play an important role, and causes an imbalance of excitation and 
inhibition throughout life. 
The patient with ADAM22 variants is asymptomatic at birth but at 2-3 
months of age, the disease progressed rapidly with recurrent, 
pharmacoresistant seizures. A remarkable feature of the disease is the rapidly 
progressing cerebral atrophy that became apparent two months after the 
disease onset. It is possible that the frequent seizure activity contributes to 
the cortical atrophy but ADAM22 dysfunction may also have a direct negative 
effect on neuronal development. The symptom onset of the patient is in line 
with the Adam22 knockout mice, which develop lethal seizures at two 
postnatal weeks. These symptoms in our patient and in the mice comply not 
only with the proposed function of ADAM22 in the functional maturation of 
synapses (Figure 14), but also with the temporal expression pattern of 
ADAM22, which increases substantially at postnatal stages (III, figure e-5).  
Our patient is alive at the age of 26 and the disease has remained stable 
after initial rapid progression. The cause for the less dramatic clinical course 
of our patient compared to Adam22-/- mice may be that the frameshift 
deletion occurs in exon 27, which is alternatively spliced and not expressed in 
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all known ADAM22 isoforms (III, figure e-4). This exon is not present in 
the peripheral nervous system but expressed widely in the CNS, where its 
prenatal expression is lower compared to other ADAM22 exons, but 
postnatally, it reaches the same level (Sagane et al. 2005; Özkaynak et al. 
2010). In accordance with the absence of exon 27 from peripheral nervous 
system, Adam22-/- mice show defective myelination in peripheral neurons, 
which, however, appears to be normal in the patient. Only few other exons 
encoding cytoplasmic parts of ADAM22 are alternatively spliced and 
expressed only in the CNS. This may be one reason why ADAM22-associated 
encephalopathy appears to be very rare. It remains to be seen what the 
symptoms would be if both biallelic loss-of-function variants affect exons 
that are not alternatively spliced. Those variants could be embryonic lethal or 
lethal in early life as in the mouse model. In any case, identification of 
additional affected individuals with ADAM22 variants would confirm that 
biallelic loss-of-function variants in ADAM22 are associated with a disease 




We utilised WES to characterise genetic causes of severe epileptic syndromes 
in patients who had remained without molecular diagnosis prior to the study. 
We hypothesised that the study cohorts may be enriched for novel genetic 
findings with the potential to increase our understanding of biological 
mechanisms underlying syndromes with epilepsy.  
Importantly, we identified two new, definite disease genes, KCNC1 and 
UBA5, whose characterisation provides new insight on the molecular genetic 
basis of these syndromes affecting the CNS. In KCNC1, we unexpectedly 
characterised a single, recurrent de novo missense mutation, which explains 
a substantial proportion of unsolved sporadic or autosomal dominantly 
inherited PME cases. We termed the new worldwide PME subtype caused by 
the recurrent KCNC1 mutation as MEAK. In UBA5, we described autosomal 
recessively inherited variants that cause a severe, infantile-onset 
encephalopathy. This UBA5-associated syndrome is likely to be present 
throughout populations of European descent, because the missense variant 
present in all five identified UBA5 families is relatively frequent in 
Europeans, in Finns in particular. Finally, identification of ADAM22 loss-of-
function variants in a patient with rapidly progressing encephalopathy with 
seizures further implicates that LGI1-ADAM22/23 complex plays an 
important antiepileptogenic role in the synapses, a hypothesis originally 
derived from biochemical studies and mouse models. However, to confirm 
the causal role of ADAM22 dysfunction in human epilepsies, identification of 
additional patients is needed. 
The three disease genes characterised in this study represent distinct 
molecular pathways. KCNC1 encodes a potassium ion channel KV3.1, which 
functions in the generation of high-frequency action potentials in the CNS. 
While ion channels underlie many epilepsy syndromes, KV3.1 is the first one 
linked to PMEs. KV3.1 is a key potassium channel in inhibitory interneurons 
and thus we hypothesise that reduced neuronal inhibition is the underlying 
epileptogenic mechanism. However, since MEAK patients also have ataxia, 
and many of them present with cognitive dysfunction and cerebellar atrophy, 
consequence of KV3.1 dysfunction in the CNS is not limited to promoting 
seizure activity. 
Disinhibition likely plays a role also in ADAM22-associated epilepsy, 
given that the LGI1-ADAM22 complex is expressed in inhibitory 
interneurons and its dysfunction has been shown to impair the excitatory 
input of the interneurons, leading to reduced inhibitory signalling. However, 
the impairment of LGI1-ADAM22 in excitatory neurons may lead to 
hyperexcitation, so likely a combination of hyperexcitation and disinhibition 
underlies the seizure phenotype when this complex is affected.  
In study II, we determined that biallelic UBA5 variants cause a partial but 
not complete attenuation of UFM1 activation by UBA5, which likely leads to 
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decreased number UFM1-target protein conjugates in a cell. Compared to 
KV3.1 and ADAM22, the mechanism how UBA5 and UFM1-system 
dysfunction leads to impaired CNS development and more specifically, 
epileptogenic activity, is more challenging to decipher, mainly because the 
role of UFM1-conjugation in the CNS has not been characterised. One 
possibility is that the pathomechanism underlies the previously implicated 
role of UFM1-system in the protection from ER stress induced apoptosis.  
For all the three genes implicated in this study, further functional work is 
required to address the disease mechanisms in the context of neuronal 
networks and whole brain. It is to be noted that in none of the three 
syndromes identified in this study symptoms are limited to epileptic seizures. 
This indicates that the dysfunctional proteins play a key role in molecular 
pathways that are fundamental for various aspects of the CNS development 
and function. Presence of a variety of CNS symptoms in patients with a single 
genetic defect complies with the emerging theme that in rare and common 
neurological, neurodevelopmental and neuropsychiatric diseases the 
underlying genetic loci and biological mechanisms are partially shared and 
do not always agree with the clinically determined disease entities. 
Our findings highlight the power of WES not only in identification of new 
disease genes but also in being able to expand genotype-phenotype 
associations in previously established disease genes. In addition to the 
identification of KCNC1 in study I, we broadened the variety of clinical 
features associated with pathogenic variants in known PME genes and in 
those originally linked to other related epilepsy or neurodegenerative 
disorders. The ‘genotype-first’ approach, enabled by WES, made it possible to 
obtain a specific diagnosis for 31% of individuals in the clinically highly 
heterogeneous PME cohort, which had been subjected to previous molecular 
testing in known disease genes. The majority of solved cases were sporadic, 
which represents another factor why traditional genetic approaches would 
not have been able to provide most if any of the diagnoses. Presence of novel 
and clinically unexpected genetic findings in our cohort supports the 
utilisation of WES or WGS over gene panels in clinically heterogeneous 
cohorts of epilepsy patients. Altogether, findings in the PME cohort improve 
molecular diagnostics, demonstrate the importance of de novo mutations 
and aid the search for potential therapeutic interventions in PMEs. The 
exome data of still unsolved cases also serves as resource to identify 
additional PME genes.  
An important message of this study is the power of collaboration. In the 
PME study, an international clinical cooperation extending to over 25-year 
period enabled establishment of a sample collection large enough in size to 
make significant progress in understanding the genetic basis of this very rare 
disease entity. In study II, we collaborated with the nationwide UK-based 
DDD study to identify two additional patients with UBA5 variants. The DDD 
study is an example of a project, which truly promotes disease gene 
identification by sharing its massive amount of genetic and phenotypic data 
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via DECIPHER database and the European Genome-phenome Archive. 
Individual research centres and even individual countries simply do not often 
have the numbers to match what is required to increase our knowledge of 
genetics of rare and common disorders. When isolated collections are 
combined, identification of new genes is greatly facilitated. Here, this was 
exemplified by the discovery of the globally occurring MEAK, which is locally 
rare because it is caused by a sporadic de novo mutation with no 
geographical hotspots. Collaboration is also important in other levels of 
genetics research. In functional work, we collaborated with groups having 
years of experience with the proteins of interest, which enabled efficient and 
high-quality testing of the pathogenicity of the newly identified variants.  
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7 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
This thesis and work by others demonstrate that NGS technologies have 
revolutionised gene discovery in Mendelian disorders. It is easy to predict 
that WES and WGS have an increasingly important role in routine 
diagnostics in the upcoming years. Indeed, the importance of the genetics-
driven approach in medicine is recognised, for example, by UK- and US-
based funding bodies that have budgeted hundreds of millions of dollars 
altogether to perform WGS in both rare and common disorders.  
The biggest obstacle to utilisation of NGS in gene diagnostics is not 
anymore in producing the sequence data, which is now fast and relatively 
inexpensive; however, bearing in mind that in resource-poor countries NGS 
methods are still largely inaccessible. Instead, the major challenges are in the 
informatics side. WGS in particular, which produces tens of gigabytes of data 
per genome, causes substantial expenses related to requirements for data 
storage and computing power. Improving interpretation of the clinical 
significance of genetic variation, both in coding and non-coding regions, is a 
major hurdle to overcome. Over the past years, it has become evident that the 
complex nature of the genomic variation not only makes it challenging to 
detect needles from the genomic haystack but it is equally easy to incorrectly 
consider truly benign variation as the cause of the disease. Misinterpretation 
of the significance of variants has major consequences to both genetic 
counselling and determination of appropriate treatment for patients. 
Therefore, best practices of variant interpretation, such as those suggested by 
ACMG (Richards et al. 2015), should be followed when analysing genetic 
data. One laudable effort to improve clinical interpretation of genetic 
variation is ClinGen, which is a resource aiming to facilitate sharing of 
genomic data as well as to curate gene-phenotype relationships and variant 
pathogenicity classifications (Rehm et al. 2015). Moreover, it aims to develop 
machine-learning methods to facilitate interpretation of the clinical impact of 
genetic variants.  
The majority of exome-sequenced patients remain unsolved in most 
studies, including ours. WGS, which captures virtually all types of genetic 
variants, is a natural step forward and likely increases the number of 
diagnoses (Gilissen et al. 2014). Given the rarity of most genetic disorders, 
data sharing is also of high importance to increase diagnostic yield. As an 
example, Epilepsy Genetics Initiative aims to gather exomes of unsolved 
patients from collaborating partners and reanalyse them collectively. The 
results are then returned to referring clinicians. 
It has been intriguing to observe how social media and improved genetic 
diagnostics have allowed patients and their families to become increasingly 
involved in the process of sharing knowledge about genetic disorders and 
enhancing precision medicine. Families with specific genetic disorders have 
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established organisations, which act as patient advocacy groups, increase 
awareness of the disorder, share information between the families, provide 
peer-support and raise funds for research. There are several patient 
organisations in epilepsy syndromes, and also in MEAK, the new subtype of 
PME identified in this study, families have been in contact with each other 
and shared their experiences with the disease. A foundation for MEAK 
research is also being established by one of the families. Importantly, 
families have also started to have an active role in trying to find the cause of 
their disease. WES or WGS often yields variants in a gene that has not been 
linked to human disease. There are now several examples where parents have 
not remained passive with this inconclusive situation. Instead, they use social 
media to try to reach other families or researchers, who have patients with 
variants in the same gene. In one example, parents used social media to find 
other patients and this led to establishment of a new genetic syndrome in 
short time (Enns et al. 2014). This highlights how important it is to connect 
isolated patients with ultra-rare conditions.  
How can the increasing knowledge of genetics be translated into targeted 
therapies? In epilepsies and most other disease entities, it is not an easy task, 
given the wide spectrum of underlying molecular pathways. It is promising to 
see, however, that already now some genetic diagnoses can lead to targeted 
therapies in epilepsies, a topic which is covered in section 2.4.3. In general 
however, it has been estimated that only 5% of human genes are both 
druggable and related to human disease, which poses challenges for 
development of new therapies (Hopkins and Groom 2002; Cheng et al. 
2007). Intriguingly, MEAK represents a genetic disorder where small-
molecules targeting the defective protein have been discovered. As 
mentioned in section 5.1.3.2, activating compounds for the KV3.1 potassium 
channel have been isolated, which is encouraging in terms of potential 
therapeutic interventions of MEAK where KV3.1-mediated potassium 
currents are reduced. The effect of these compounds on the mutant KV3.1 
channel will be tested using in vitro systems and a knock-in mouse with the 
analogous recurrent mutation in Kcnc1.  
In Mendelian disorders, which are due to defects in single genes, gene 
therapy is a promising therapeutic approach. In gene therapy, genetic 
material is inserted into patient cells with the aim to either knock out 
mutated copy of the gene, replace a mutated gene with a functional one or 
deliver a new gene into the cell. However, reaching adequate specificity and 
efficiency has been the major obstacle of gene therapy. A highly promising 
tool to increase specificity is CRISPR-Cas9 genome editing tool, which is 
likely to become one of the most influential technologies in the history of 
molecular biology. It has been shown to be a precise and simple tool to make 
specific changes in DNA. It can be used, for example, to inactivate a gene by 
making a deletion in a specific site or to correct DNA sequence. Recently, 
CRISPR-Cas9 system has been successfully delivered to mouse neurons in 
vivo using adeno-associated viral vectors with high efficiency (Swiech et al. 
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2015). More compact and more precise versions of the CRISPR-Cas9 tool 
have since been introduced, providing increasing hope for therapeutic utility 
of this approach in a variety of genetic disorders (Ran et al. 2015a; Slaymaker 
et al. 2016). Adeno-associated viral vectors can be used to deliver genetic 
material into human CNS but the efficiency of this method to transduce 
target cells needs still improvement (Bourdenx et al. 2014). Yet, CRISPR-
Cas9 system represents a highly tempting therapeutic approach in MEAK 
and other genetic disorders to correct the genetic defect. The utility of this 
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